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Abstract 
 
We conducted a systematic review and meta-analysis to assess the association of MTX 
with cardiovascular morbidity, cardiovascular mortality and all-cause mortality in patients 
with autoimmune disease. Our primary outcome was incident cardiovascular events. After 
screening 13,479 citations, we identified a total of 30 eligible studies. We synthesized 
adjusted risk estimates using a random effects model. MTX was significantly associated 
with a 25% reduction in cardiovascular events (pooled RR: 0.75, 95% CI: 0.65, 0.86, I
2
: 
11%), a 55% reduction in cardiovascular mortality (0.45, 95% CI: 0.26, 0.80, I
2
: 33%) 
and a 40% reduction in all-cause mortality (0.60, 95% CI: 0.48, 0.76, I
2
: 45%). Low-dose 
MTX was associated with a stronger effect size for reducing cardiovascular events 
compared to high-dose MTX (0.61, 95% CI: 0.51, 0.74 versus 0.88, 95% CI: 0.78, 0.99). 
We concluded a significant associative reduction in cardiovascular events with the use of 
low-dose MTX in patients with autoimmune disease. 
Keywords: Methotrexate, autoimmune disease, cardiovascular events, mortality, 
rheumatoid arthritis, psoriasis, systematic review, meta-analysis   
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Chapter 1: Introduction 
 
1. Overview 
The objective of this thesis is to quantify the association of methotrexate (a commonly 
used therapy for a variety of autoimmune conditions) with cardiovascular morbidity, 
cardiovascular mortality and all-cause mortality in patients with autoimmune disease. We 
conducted a systematic review and meta-analysis of trials and observational studies 
meeting restricted eligibility criteria. We included autoimmune diseases in which 
methotrexate has been used as one of the treatment options. We used the Newcastle-
Ottawa scale for quality assessment of observational studies, and the Cochrane risk of 
bias instrument to appraise the quality of randomized trials.
1,2
 
2. Scope of the problem 
Cardiovascular diseases such as coronary artery disease, peripheral arterial disease, 
stroke, and venous thromboembolism are the leading cause of morbidity and mortality in 
developed as well as developing countries, accounting for 30% of all deaths worldwide in 
2008.
3
 Of these deaths, an estimated 42% of deaths were a result of coronary artery 
disease and 36% of deaths were attributed to stroke.
4
 Cardiovascular disease has no 
geographic, socioeconomic or sex boundaries. According to World Health Organization 
(WHO) data published in 2011, 80% of deaths among young individuals in low and 
middle income countries were due to cardiovascular disease.
3
 Moreover, costs of treating 
cardiovascular disease are among the highest for chronic diseases. These costs constituted 
17% of all annual medical expenditures in the United States, 12% in the European Union 
and 17% in the United Kingdom.
5,6
 In Canada, while the death rate from cardiovascular 
disease declined in the last decade, mortality from cardiovascular disease remained the 
second leading cause of death after cancer (and 25.2% of all deaths).
7
 Despite improved 
management and optimal patient care, cardiovascular disease remains the largest single 
contributor to mortality worldwide. WHO estimates annual deaths due to cardiovascular 
disease to reach more than 23 million by 2030.
3
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The global burden of cardiovascular disease will continue to increase due to multi-
dimensional effects of cardiovascular risk factors and population aging. Cardiovascular 
disease is not only caused by major individual cardiovascular risk factors but also by 
other contributing conditions that alter these risk factors, directly or indirectly. Some 
novel risk factors for cardiovascular disease include high levels of C-reactive protein, 
lipoprotein (a), homocysteine, LDL-c particle size and fibrinogen.
8-10
 Various chronic 
medical conditions such as end-stage renal disease, chronic inflammatory connective 
tissue diseases, and human immunodeficiency virus infection are also considered to be 
risk factors for cardiovascular disease.
10
 In addition, disturbances in tissue plasminogen 
activator (tPA) levels and low serum testosterone are known to contribute to 
cardiovascular disease.
11,12
 Other situations including hysterectomy before the age of 50 
and psychosocial conditions such as mental stress, depression and poor sleep quality are 
also risk factors for cardiovascular disease.
10
  
Some of the above risk factors such as hypertension, diabetes mellitus, dyslipidemia, 
smoking, obesity and physical activity can be modified and controlled while others 
cannot. Declining trends in cardiovascular mortality over the past few decades have been 
observed due to increased awareness, improved management of modifiable risk factors 
and medical treatment of patients with cardiovascular disease.
13,14
 A number of health 
promotion and prevention programs have also played an important role. Conversely, due 
to increased prevalence of physical inactivity, obesity, diabetes, high calorie consumption 
and other risk factors, global morbidity and mortality from cardiovascular disease remains 
high. Considering the global burden of cardiovascular disease and the health 
consequences for individual patients, there is a significant need to address other 
preventive measures for cardiovascular disease that are associated with novel and non-
traditional risk factors.   
Until now, scant attention has been paid to addressing some of these novel risk factors 
that may have importance in ameliorating cardiovascular disease. Autoimmune diseases 
are one of these risk factors. The enhanced risk of cardiovascular disease in major 
autoimmune disease is a significant clinical problem.  
3 
 
 
 
Autoimmune diseases represent a variety of disease manifestations and jointly they affect 
5-10% of the population in developed countries.
15,16
 Disease activity and severity are 
associated with high mortality in patients with autoimmune disease; yet with the 
availability of better therapies, the lifespan of these patients has improved. Hence in part 
due to improved survival, the long-term consequences of these diseases such as coronary 
artery disease and stroke are increasingly manifest. Autoimmune diseases cause chronic 
inflammation and immune dysregulation, which lead to increased autoantibody 
production, dyslipidemia, platelet dysfunction and vascular pathology, which are 
consequently responsible for atherosclerosis.
17,18,19 
Thus, premature atherosclerosis is 
more frequent in patients with systemic autoimmune conditions.  
A broader concept of therapy targeting inflammation is needed to reduce morbidity and 
mortality due to cardiovascular as well as autoimmune disease. Different 
immunotherapeutic agents are in use to treat various autoimmune conditions. The effect 
of these therapeutic agents on the cardiovascular system and mortality remains a vital 
issue. One routinely used agent is methotrexate (MTX). 
3. Relationship of autoimmune disease with cardiovascular disease, 
cardiovascular mortality and all-cause mortality 
3.1 Rheumatoid arthritis 
Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease affecting multiple 
joints that leads to joint destruction, deformity, loss of function and reduced life 
expectancy. Due to the inflammatory nature of the disease, RA patients are more prone to 
develop cardiovascular disease than the general population.
20,21
 Several studies also 
identified  a higher cardiovascular and all-cause mortality in RA patients compared to the 
general population.
22
 In a cohort study, Young et al identified a standardized mortality 
ratio (SMR) of 1.27 (95% CI: 1.04, 1.46) in RA patients compared to the general 
population in the United Kingdom.
22
 In another population based cohort study, Turesson 
et al reported an age and sex adjusted standardized morbidity ratio of 1.61 (95% CI: 1.21, 
2.10) for first ever acute myocardial infarction or stroke in RA patients compared to the 
Malmo, Sweden general population.
23
 Maradit-Kremers et al found a hazard ratio (HR) of 
4 
 
 
 
2.41 (95% CI: 1.00, 5.81) for cardiovascular death in RA patients with concomitant 
vasculitis compared to RA patients without vasculitis.
24
 
3.2 Psoriasis 
Psoriasis is a chronic inflammatory autoimmune disease of skin characterized by red 
elevated patches and flaking silvery scales. Severe psoriasis appears to be associated with 
an increased risk of cardiovascular morbidity and mortality. A study conducted by 
Gelfand et al reported an incidence rate of 5.13 (95% CI: 4.22, 6.17) per 1000 person 
years for myocardial infarction in patients with psoriasis in contrast with 3.58 (95% CI: 
3.52, 3.65) per 1000 person years in the control group.
25
 In a recently published meta-
analysis, Horreau et al reported an odds ratio of 1.19 (95% CI: 1.14, 1.24) in cross-
sectional studies, 1.20 (95% CI: 1.13, 1.27) in cohort studies, and 1.84 (95% CI: 1.09, 
3.09) in case-control studies for the risk of coronary artery disease in psoriasis patients 
compared to patients without psoriasis.
26
 For mortality, Abuabara et al conducted a 
population-based cohort study and found a higher overall death rate (26, 95% CI: 23, 29 
per 1000 patient-years) in psoriasis patients compared to patients without psoriasis (18, 
95% CI: 17, 19 per 1000 patient-years).
27
  
3.3 Psoriatic Arthritis 
Psoriatic arthritis is an inflammatory arthritis associated with psoriasis. Like psoriasis and 
RA, psoriatic arthritis also carries a high risk of cardiovascular morbidity and mortality. 
A cohort study from Toronto, Ontario identified high cardiovascular and all-cause 
mortality in patients with psoriatic arthritis compared to the general population, with a 
standardized mortality ratio of 1.62 (95% CI: 1.21, 2.12).
28
  
3.4 Systemic sclerosis 
Systemic sclerosis is a multisystem autoimmune disease characterized by abnormal 
growth of connective tissue and fibrosis. Barnes and Mayes found higher mortality in 
systemic sclerosis patients compared to the general population, with a standard mortality 
ratio of 1.46 (95% CI: 1.28, 1.69).
29
 Additionally, they noted that 55% of deaths in 
systemic sclerosis patients were directly related to the disease itself and 14% of deaths 
were due to systemic sclerosis-related myocardial disease. A retrospective analysis 
carried out by Man et al from the General Practitioner database in the United Kingdom 
5 
 
 
 
reported a two-fold increase in the risk of myocardial infarction and stroke in systemic 
sclerosis patients compared to those without systemic sclerosis.
30
 
3.5 Systemic Lupus Erythematosus  
Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease of various 
manifestations affecting skin, joints, kidney, brain, and other organs. Petri et al observed 
that the prevalence rate of cardiovascular disease ranged from 6 to 10% in individuals 
with SLE.
31
 The mortality rate in SLE is 2-5 times higher than that of the general 
population.
32
 Yurkovich et al demonstrated a three-fold increased risk of death in SLE 
patients compared to the general population, with a pooled standardized mortality ratio of 
2.98 (95% CI: 2.32, 3.83).
33
 They also showed a standardized mortality ratio of 2.72 
(95% CI: 1.83, 4.04) due to cardiovascular disease in SLE patients compared with the 
general population.  
3.6 Dermatomyositis and polymyositis 
Dermatomyositis (DM) is a connective tissue disorder characterized by inflammation of 
muscle and skin. As a systemic disorder, it may affect the joints, esophagus, lungs, and 
heart. Polymyositis causes muscle inflammation and diffuse weakness of both sides of the 
body, mainly affects proximal muscles. In Finland, Airio et al carried out a retrospective 
analysis of dermatomyositis and polymyositis patients from a hospital database.
34
 They 
showed a standardized mortality ratio of 2.92 (95% CI: 2.82, 3.44) in these patients. In 
this cohort, the main cause of mortality was cardiovascular disease (in 31% of 
dermatomyositis patients).  
3.7 Multiple sclerosis 
Multiple sclerosis (MS) is a chronic inflammatory, debilitating disease of the nervous 
system, resulting in various signs and symptoms. A higher mortality rate is observed in 
patients with multiple sclerosis compared to the general population.
35
 A recently 
published population-based cohort study observed a 3.5-fold all-cause mortality rate in 
multiple sclerosis patients compared to the reference population with a hazard ratio of 
3.51 (95% CI: 2.63, 4.69).
36
 In the same study, the hazard ratio due to cardiovascular 
death in multiple sclerosis patients was found to be 2.42 (95% CI: 1.47, 3.97).  
6 
 
 
 
3.8 Sjogren’s syndrome  
Sjogren’s syndrome is an inflammatory disease of the immune system that can affect 
different parts of body but most commonly affects the eye and salivary glands. Previous 
studies have identified evidence of metabolic abnormalities in primary Sjogren’s 
syndrome that may increase the risk of stroke and cardiovascular disease in these 
patients.
37
 However, Chiang et al reported an adjusted hazard ratio of 0.84 (95% CI: 0.62, 
1.12) for ischemic stroke in primary Sjogren’s patients compared to a non-Sjogren’s 
control group.
38
 There was no difference in the survival between Sjogren’s syndrome and 
the healthy population. Theander et al and Nannini et al reported non-significant 
differences in mortality between patients with Sjogren’s syndrome and the general 
population.
39,40
  
3.9 Bullous pemphigoid 
Bullous pemphigoid (BP) is a chronic, autoimmune, subepidermal, blistering disease of 
skin that often affects the lower abdomen, upper thighs or armpits. In Langan et al, 
patients with bullous pemphigoid had more than twice the all-cause mortality than that of 
the control group with an adjusted hazard ratio of 2.3 (95% CI: 2.0, 2.7).
41
 In Taiwan, 
Yang et al carried out an analysis from Taiwan’s National Insurance Research Database 
(NHIRD) and determined an adjusted hazard ratio of 2.37 (95% CI: 1.78, 3.15) for stroke 
in patients with bullous pemphigoid.
42
  
3.10 Inflammatory Bowel Disease  
Inflammatory Bowel Disease (IBD) is a group of autoimmune inflammatory conditions 
that affect the digestive system. Crohn’s disease (CD) and ulcerative colitis (UC) are the 
major types of IBD. A study conducted in Canada by Bernstein et al reported an increased 
risk of ischemic heart disease in IBD patients (both in CD and UC) with an incidence risk 
ratio of 1.26 (95% CI: 1.11, 1.44).
43
 In a cohort study, Jess et al found intermediate and 
long-term mortality rates increased by 10% (in relative terms) among patients with UC 
and 50% among patients with CD when compared with the general population.
44
 The 
authors also reported a hazard ratio of 1.20 (95% CI: 1.14, 1.26) in UC and 1.39 (95% CI: 
1.28, 1.51) in CD for death due to cardiovascular disease.
44
 Cart et al reported similar 
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results in a study from the United Kingdom with a hazard ratio of 1.54 (95% CI: 1.44, 
1.65) for deaths among IBD patients after adjusting for age, sex and smoking status.
45
 
3.11 Transverse Myelitis 
Transverse myelitis is an inflammatory disease of the spinal cord of varied etiology 
resulting from loss of spinal cord functions over several hours to weeks. Apart from 
infections and vaccinations for infectious diseases, causes of transverse myelitis also 
include several autoimmune conditions such as systemic lupus erythematosus, Sjogren’s 
syndrome, Behcet’s disease, antiphospholipid syndrome, multiple sclerosis, neuromyelitis 
optica and other rheumatic diseases.
46
  To the best of our knowledge, no data on 
cardiovascular risk exist for transverse myelitis. 
3.12 Myasthenia Gravis 
Myasthenia Gravis (MG) is a chronic autoimmune disease of neuromuscular system 
characterized by weakness and fatigue of skeletal muscle. Evidence supporting a 
relationship between myasthenia gravis and cardiovascular disease is limited. However, a 
study published in 1984 by Hofstad et al observed a relationship of heart disease with 
myasthenia gravis.
47
 The authors in this study observed that 16% of myasthenia gravis 
patients exhibited signs of heart disease. In contrast, Owe et al examined 1,992,342 
deaths from the Norwegian Cause of Death Register from 1951 to 2001 and determined 
significantly lower cardiac disease in myasthenia gravis patients compared to the controls 
in the age group 50-69 (19.4% in myasthenia gravis patients versus 52.0% in controls for 
men, p=0.001, and 14.6% versus 29.6% for women, p=0.036).
48
 
3.13 Wegener’s Granulomatosis 
Wegener’s granulomatosis is a chronic inflammatory disease of small and medium size 
vessels characterized by granuloma formation that affects many organs and requires long 
term immunosuppression therapy. It is also known as granulomatosis with 
polyangiitis (GPA). It is a rare disease with varied geographic distribution. Watts et al 
noted an increasing trend in prevalence in the United Kingdom with a prevalence rate of 
62.9 per million in December 1997 and 148 per million at the end of 2010.
49
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3.14 Microscopic Polyangiitis  
Microscopic polyangiitis (MPA) is a chronic autoimmune vasculitis characterized by 
necrosis of small size blood vessels without granulomatous inflammation. In contrast to 
Wegener’s granulomatosis, it usually affects the lower respiratory tract and is associated 
with anti-neutrophil cytoplasmic autoantibody (ANCA) directed against myeloperoxidase 
(MPO). Watts et al reported a mean annual incidence of 5.9 per million population (95% 
CI: 4.4, 7.5) for MPA in the United Kingdom during the period of 1988-2010.
49
 They also 
noted an increasing trend in prevalence for GPA and MPA in the United Kingdom.  
3.15 Eosinophilic Granulomatosis with Polyangiitis 
Eosinophilic granulomatosis with polyangiitis (EGPA) is one of three ANCA-associated 
vasculitides, predominantly affecting small size blood vessels. It is also known as a 
Churg-Strauss Syndrome (CSS).  
GPA, MPA and EGPA are also known as ANPA-associated vasculitis. In these patients, 
an increased mortality due to cardiovascular disease is well-documented. The relative risk 
for coronary heart disease and stroke in ANCA-associated vasculitis is 2 to 4-fold higher 
than that in control patients.
50
 ANCA-related vasculitis patients may experience 
accelerated atherosclerosis.
50
  
3.16 Takayasu’s Arteritis  
Takayasu’s arteritis (TA) is a rare, systemic inflammatory vasculitis of large vessels 
leading to abnormal stenosis or aneurysm of vessels. Affected patients are more prone to 
accelerated atherosclerosis. About 10-30% and 10-20% of Takayasu’s arteritis patients 
experience coronary artery disease and stroke respectively due to hemodynamic 
compromise in large artery stenosis and thromboembolism.
50
  
 
Overall, autoimmune disease are associated with increased risk of cardiovascular events, 
cardiovascular mortality and all-cause mortality worldwide.
51-54
 Autoimmune disease is 
one of the top ten causes of death and mostly affects women.
51
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4. Mechanisms of cardiovascular disease in autoimmune disease 
Development of cardiovascular disease relies on the contributions of both genetic and 
environmental risk factors. Evidence supports the association of atherosclerosis with 
chronic inflammation. Shoenfeld et al note the absence of traditional cardiovascular risk 
factors in approximately 40% of patients with myocardial infarction or stroke and suggest 
an involvement of inflammatory and immune mechanisms in the rapid development of 
atherosclerosis.
55
 They also identified the participation of several autoantigens and 
autoantibodies in the process of atherosclerosis. 
 
 
Figure 1. Components of immune system in the process of atherosclerosis. 
(Source: Sherer and Shoenfeld)
56
. Reproduced with permission. 
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4.1 Atherosclerosis in autoimmune disease 
Atherosclerotic plaque is characterized by accumulation of lipid particles and immune 
cells in the artery’s subendothelial region. Components of the immune system involved in 
the process of atherosclerosis include macrophages, T-cells, autoantibodies, autoantigens, 
LDL particles, cytokines including tumor-necrosis factor (TNF), interleukin 1 (IL-1), IL-
2, IL-6, IL-8, IL-10, IL-12, interferon-γ and platelet-derived growth factor (Figure 1).56 
In RA, several factors accelerate the process of atherosclerosis, including lifestyle, 
modifiable risk factors, lipid dysregulation, chronic inflammation, immune dysregulation, 
functional abnormalities of the vascular endothelium, and expansion of CD4+CD28- 
cells.
17
 In SLE, high prevalence of modifiable cardiovascular risk factors, increased 
inflammatory markers, coronary artery calcification and increased levels of oxidised LDL 
(oxLDL) are associated with accelerated atherosclerosis.
56
  
The exact mechanism of atherosclerosis is not yet clear in systemic sclerosis. However, 
based on available evidence, it can be inferred that atherosclerosis and vascular disease in 
systemic sclerosis is caused by several factors such as impaired coronary 
microcirculation, endothelial injury, intimal thickening, destruction of the internal elastic 
lamina, transmural lymphocytic cellular infiltration and increased intimal-medial 
thickness of the major vessels.
17
  
GPA, MPA and ECGA are types of primary systemic vasculitides (PSVs) which may 
trigger atherosclerosis through inflammation and immune reaction. In these diseases, due 
to a vascular bed lesion, inflammation and in-situ immune reactions activate the 
endothelial cells in the vessel’s intima. This further exposes adhesive molecules to secrete 
cytokines, chemokines, growth factors and metalloproteinases at the site resulting in rapid 
atherosclerosis.
17
 Several factors such as increased intimal-medial thickness, C-reactive 
protein, matrix metalloproteinases, several pathological autoantibodies and oxidised LDL 
are responsible for the accelerated atherosclerotic process in the primary systemic 
vasculitides.
17
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5. Methotrexate 
Methotrexate (MTX) is a disease-modifying anti-rheumatic drug (DMARD) which 
reduces inflammation in autoimmune disease by suppressing the immune system. While 
originally designed to treat cancer as a chemotherapeutic agent, it has proven safe and 
well-tolerated in several autoimmune conditions when used in low doses. It is commonly 
used as part of the standard of care in first, second or third-line therapy in various 
autoimmune diseases. Its safety and efficacy have been proved in placebo-controlled 
trials as well as in active comparator trials using other disease modifying anti-rheumatic 
drugs.
57,58
 
Methotrexate’s potential cardioprotective effects may operate through reducing systemic 
inflammation and by a direct effect on the cellular mechanisms responsible for 
atherosclerosis. Cutolo et al reviewed different anti-rheumatic and anti-inflammatory 
mechanisms of MTX.
59
 In their review, they noted that low-dose methotrexate exerts both 
anti-proliferative and anti-inflammatory effects through different pathophysiological 
mechanisms. Describing the first mechanism, MTX increases extracellular adenosine, 
which interact with specific cell surface receptors (A2A and A3) and inhibits IL-8, IL-6, 
and leukotriene B4. Secondly, MTX reduces the production of pro-inflammatory 
monocytic and macrophagic cytokines, including IL-1, IL-6, and TNF-α. Furthermore, 
MTX increases the gene expression of anti-inflammatory Th-2 cytokines (IL-4, IL-10) 
and decreases the gene expression of pro-inflammatory Th-1 cytokines (IL-2, IFNγ).59  
Coomes et al also describe mechanisms by which MTX reduces atherosclerosis.
60
 
According to their review, MTX activates A2A and A3 adenosine receptors by releasing 
adenosine, which consequently up-regulates expression of ABCA1 and 27-hydroxylase. 
Steps and details of these mechanisms are described in the following Figure 2. 
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Figure 2. Anti-atherogenic mechanisms of MTX 
13 
 
 
 
6. Study rationale 
To date, no clinical trial has been conducted addressing the direct association of MTX use 
and cardiovascular morbidity and mortality in patients with rheumatic and autoimmune 
disease. Currently, the Cardiovascular Inflammation Reduction Trial (CIRT) is ongoing 
and recruiting patients to investigate the effect of low-dose MTX on the rate of recurrent 
cardiovascular events in patients with prior myocardial infarction plus either type 2 
diabetes or the metabolic syndrome.
61,62
 However, CIRT is focused on an established 
secondary prevention population while excluding patients with autoimmune disease who 
are also at risk.  
Observational studies including cross-sectional, case-control and cohort studies have 
addressed the association between the effect of methotrexate and cardiovascular 
morbidity and mortality in patients with RA, psoriasis, SLE, and psoriatic arthritis.
63-71
 
These studies are observational and thus not free from the limitations and weaknesses 
related to their nonrandomized design. Such studies are subject to two major types of 
bias. The first is ‘confounding by indication’, whereby in real world clinical practice, 
sicker patients with a greater indication for treatment would be more likely to get 
methotrexate than less sick patients. Additionally, these patients may have high 
inflammation, which leads to increased risk of cardiovascular disease. The second type of 
bias is ‘physician selection bias’, where there is a likelihood of selecting methotrexate 
over other DMARDs in practice, particularly when deciding systemic therapy for 
psoriasis patients. A non-randomized comparison due to these biases either 
underestimates or overestimates the effect of methotrexate in reducing cardiovascular 
disease.  To generate a scientifically relevant evidence and understand the relationship of 
MTX with CVD, we conducted this systematic review, focused on the good quality 
studies, and tested the results for consistency across various disease endpoints. 
Several recent reviews have studied the relationship between MTX and cardiovascular 
morbidity.
60,72-74
 Micha et al reported an overall 21% and 18% reduction in 
cardiovascular disease and myocardial infarction respectively, in patients treated with 
MTX compared to those treated with other anti-rheumatic agents.
72
 The pooled estimate 
from this review did not measure an independent effect of methotrexate since the 
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comparison group consisted of active treatment. Moreover, this meta-analysis assessed 
only ‘hard’ cardiovascular events and not ‘softer’ events such as heart failure. The 
authors did not assess the association of MTX with mortality. Finally, this meta-analysis 
included studies published up to June 2010 only. We are expecting to add more studies 
on the topic which were published after 2010.
63,70,75
  
Another systematic review published by Westlake et al in 2010 also found a 
cardioprotective effect of MTX, but included only RA patients.
73
 As well, this review 
was limited to cardiovascular disease and did not include mortality as a corollary 
outcome. Finally, the authors did not perform a meta-analysis to quantify the overall 
association between MTX exposure and cardiovascular disease.  
Marks and Edwards studied pathogenesis and risk factors for cardiovascular disease in 
RA patients.
74
 Coomes et al described an overview of the mechanism by which MTX 
interferes with cholesterol homeostasis and reduces atherogenesis in inflammatory 
conditions.
60
 These narrative reviews used surrogate markers and established biological 
plausibility for the protective association between MTX and cardiovascular disease. 
 
7. Research questions 
7.1 Primary question 
Is methotrexate associated with a lower risk of cardiovascular events in patients with 
autoimmune disease? 
Hypothesis: We hypothesize that treatment with methotrexate is associated with a lower 
risk of cardiovascular events in patients with autoimmune disease, even after adjustment 
for potential confounders.  
 
7.2 Secondary question 
Is methotrexate associated with a lower risk of cardiovascular mortality, all-cause 
mortality, and other cardiovascular disease endpoints such as coronary events and stroke? 
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Hypothesis: We hypothesize that methotrexate is associated with a lower risk of 
cardiovascular mortality, all-cause mortality, and cardiovascular disease endpoints in 
patients with autoimmune disease.  
7.3 Exploratory question (dose-response analysis) 
Does the association of methotrexate with cardiovascular events vary by different doses 
(high or low methotrexate doses)?  
Hypothesis: We hypothesize that treatment with high-dose methotrexate is associated 
with a lower risk of cardiovascular events than treatment with low-dose methotrexate.    
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Chapter 2: Methods 
 
1. Overview 
Using the framework of a systematic review, we quantified the associative risk of MTX 
for cardiovascular events, cardiovascular mortality and all-cause mortality in patients 
with autoimmune disease. This review was conducted in accord with the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (see 
Appendix A for PRISMA Checklist).
76
 
In terms of study designs, we evaluated cohort studies, case-control studies and 
randomized controlled trials. We selected cardiovascular events as the primary outcome, 
given its biological relevance to MTX’s mechanism of action. We included autoimmune 
diseases for which MTX is used as a treatment agent in first, second or third line therapy. 
We evaluated the association of MTX with events according to a number of parameters 
including type of autoimmune disease, demographic factors, dose-response, observation 
period and other potential sources of heterogeneity. We registered our study protocol with 
the International Prospective Register of Systematic Reviews. 
2. Criteria for considering studies  
To identify relevant studies, we prespecified the following criteria for types of 
autoimmune disease, treatment and control groups, and outcomes. 
2.1 Study patients  
The autoimmune diseases included in this systematic review are rheumatoid arthritis, 
psoriasis, psoriatic arthritis, dermatomyositis, polymyositis, systemic lupus 
erythematosus, multiple sclerosis, Sjogren’s syndrome, bullous pemphigoid, Crohn’s 
disease, ulcerative colitis, transverse myelitis, systemic sclerosis, myasthenia gravis, 
Wegener’s granulomatosis, microscopic polyangiitis, eosinophilic granulomatosis with 
polyangiitis and Takayasu’s arteritis. We prepared this list of eligible autoimmune 
diseases by comprehensively searching the online reference “UpToDate”, and by 
reviewing clinical textbooks of rheumatology.
77
 Two investigators, a clinical 
pharmacologist and a practicing rheumatologist (specializing in vasculitis), reviewed this 
list and finalized the diseases to be included in this meta-analysis. We included 
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autoimmune diseases for which MTX is used as a treatment agent in first, second or third 
line therapy. 
2.2 Intervention and comparison group  
The included study must compare MTX users to non-users (either placebo or a no-MTX 
comparator group). 
2.3 Outcomes measured 
We included studies that reported any of the following outcomes: cardiovascular events 
(including composite cardiovascular endpoints), fatal or non-fatal myocardial infarction, 
coronary artery disease, acute coronary syndrome, heart failure, cardiac arrest, sudden 
cardiac death, hospitalization due to cardiovascular events, stroke, cardiovascular 
mortality and all-cause mortality. We defined all our outcomes using International 
Classification of Diseases version 10 (ICD-10) criteria.
78
 
a. Cardiovascular events (ICD-10: I00-I99): In this category, we considered composite 
cardiovascular endpoints which include any of the following events: fatal or non-fatal 
myocardial infarction, angina pectoris, coronary interventions such as coronary 
bypass grafting or percutaneous coronary intervention, acute heart failure, peripheral 
arterial disease, vascular surgery, ischemic stroke, transient ischemic attack, and 
carotid endarterectomy.  
b. Coronary events (ICD-10: I20-I25): This includes angina pectoris, myocardial 
infarction and complications associated with myocardial infarction. We also included 
any hospitalization or death due to coronary events in this group.  
c. Myocardial Infarction (ICD-10: I21-I23): This includes fatal or non-fatal myocardial 
infarction along with acute (ICD-10: I21) and subsequent (ICD-10: I22) myocardial 
infarction and its complications (ICD-10: I23).  
d. Acute Coronary Syndrome ICD-10: I24.9):  This refers to conditions attributed to 
acute obstruction of a coronary artery. We also included any hospitalization due to 
acute coronary syndrome in this endpoint.  
e. Heart Failure (ICD-10: I50): This refers to chronic or congestive heart failure, left 
ventricular failure, unspecified heart failure and heart failure requiring hospitalization.  
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f. Ischemic stroke (ICD-10: I63): This includes both fatal and non-fatal cerebral 
infarction due to occlusion of cerebral arteries as a result of embolism or thrombosis.  
g. Cardiac arrest (ICD-10: I46.9): This comprises hospitalization or death due to cardiac 
arrest. 
h. All-cause mortality: This includes death from any cause. 
i. Cardiovascular mortality (ICD-10: I00-I99): Any death due to disease of the 
circulatory system, including coronary heart disease, stroke, hypertensive diseases, 
inflammatory heart diseases, rheumatic heart diseases, and other cardiovascular 
diseases. 
2.4 Reporting of adjusted risk estimates 
Eligible studies could report the outcome of interest in terms of adjusted relative risk 
estimates (risk ratios, odds ratios, hazard ratios, standardized morbidity or mortality 
ratios) and accompanying 95% confidence intervals, p-values, z-scores, or standard 
errors. Observational studies that reported only crude or unadjusted risk estimates were 
deemed ineligible. Trials could include unadjusted estimates including dichotomous 
event data. 
3. Literature search 
We developed a comprehensive literature search strategy with the help of a clinical 
librarian. First, we identified all possible terms and their synonyms related to this study’s 
PICO (population, intervention, control and outcome) and then transferred them into a 
primary search strategy for the Ovid Medline database. We used combinations of medical 
subject headings (MeSH terms) and free text keywords in this search strategy to identify 
all relevant articles.  
The primary Ovid Medline search strategy identified 1216 articles. We pilot-tested this 
strategy against relevant key articles; refined and modified it by adding further terms, 
which were identified from the test articles’ mapped keywords; and examined search 
strategies from related systematic reviews. In Table 1 (at the end of this chapter), we 
present a final list of MeSH terms and keywords used in our search strategies.  
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We limited our search to adults and human studies. Once we finalized the Ovid Medline 
search strategy, we translated it into other online bibliographic databases such as 
EMBASE, Cochrane library, Web of Science and Google Scholar using analogous terms 
pertaining to the specific database. We searched records published from the initial 
available year of indexing up to November 30, 2014 with assistance from weekly auto-
alert emails from each of the databases. The full search strategy is presented in Appendix 
B. 
Additionally, we manually searched bibliographies of eligible studies and previous 
narrative and systematic reviews. We also searched abstracts in recent years from major 
rheumatology, dermatology and gastroenterology conferences.  
4. Screening of studies 
For subsequent manipulation and review of citations, we downloaded all retrieved 
citations into RefWorks, an internet-based reference management tool. We removed all 
duplicate citations prior to study screening. A total of 13,479 records were then screened. 
The principal investigator (AS) initially screened all records by reviewing their titles, 
abstracts and keywords. Records were excluded upon initial review if they were found to 
be case reports, cross-sectional studies, reviews, letters, commentaries or guidelines. If 
the reviewer could not initially determine whether to include or exclude a record by 
screening the title, keywords and abstract, the full text of the record was reviewed to 
make a final decision. We identified a total of 187 papers for full text review.  
5. Study eligibility assessment 
We retrieved the full text of all 187 papers. We developed a standardized eligibility 
assessment form in Microsoft Excel to rate the eligibility of these records. We pre-tested 
this sheet in 20 randomly selected studies, modified it based on these results, and 
finalized it (Appendix C). Two investigators, AS and DH, independently assessed the 
eligibility of 187 full text reports using the pre-specified inclusion and exclusion criteria 
(Table 2).  
All studies were categorized as either ‘Included’ (if the study met all inclusion criteria) or 
‘Excluded’ or ‘Unclear’ in the standardized eligibility form. We recorded reasons for the 
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excluded and unclear studies. To determine reviewers’ agreement, we calculated Cohen’s 
kappa statistic (κ).79 We interpreted the value of kappa as follows: fair agreement (0.21-
0.40), moderate agreement (0.41-0.60), substantial agreement (0.61-0.80) and almost 
perfect agreement (0.81-1.00).
80
 Disagreements between reviewers were resolved by re-
evaluation of the studies, followed by discussion and consensus.  
6. Data abstraction 
We created a comprehensive data abstraction form in Microsoft Excel. The form included 
the following variables: study number, citation details, study characteristics, sample 
characteristics, disease particulars, exposure and outcome details, and analysis and results 
(Appendix D). We pilot-tested this form using five randomly selected studies and refined 
it based on the results.  
One reviewer (AS) abstracted data from the final list of selected studies for the following: 
study accrual start and end date; inclusion and exclusion criteria; demographic 
information (mean age, gender distribution); disease details such as diagnostic criteria 
and disease duration; methotrexate exposure details such as exposure definition, exposure 
type, exposure data source and dose of methotrexate (mean or median mg/kg); details of 
outcome (outcome definition, source of outcome data); and results and analysis variables, 
including number of events in each group, adjusted risk estimates with 95% confidence 
intervals, variables adjusted for, dose response analyses and subgroup analyses.  
7. Quality assessment of included studies 
We assessed the quality of included studies using the Newcastle-Ottawa-Scale (NOS) for 
non-randomized studies and the Cochrane risk of bias tool for randomized trials.
1,2
   
7.1 Newcastle-Ottawa Scale (NOS) 
The NOS was proposed by Wells et al to assess the quality of observational (non-
randomized) studies in meta-analyses. The scale was tested on systematic reviews. Its 
content validity and inter-rater reliability have been established.
1
 Deeks et al evaluated a 
total of 194 different observational study quality assessment tools, and found the NOS 
was relatively easy to use, faster to complete and suitable for use in systematic reviews.
81
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The developers of the NOS measured its validity and inter-rater reliability using several 
cohort and case-control studies and reported an intra-class correlation of 0.88 for cohort 
studies and 0.62 for case-control studies.
82
 In the same study, inter-rater reliability was 
high for both cohort (ICC=0.94) as well as case-control studies (ICC=0.82). In contrast, 
Hartling et al noted a varied range of inter-rater reliability, from slight to moderate 
agreement across the different domains of NOS.
82
 A poster presented at the 2010 
Cochrane collaboration annual colloquia by Hou et al reported fair to almost perfect 
reliability for the rating of NOS items and fair to good inter-rater correlation for the total 
score.
83
  
There are two separate Newcastle-Ottawa scales for case-control and cohort studies, 
respectively. The scale uses a ‘star’ rating system to adjudicate quality based on three 
broad domains, namely selection and comparability of study groups, and outcome in 
cohort studies and exposure in case-control studies (Appendix E). 
7.2 Cochrane Risk of Bias tool 
The Cochrane risk of bias tool is a widely used tool to assess the internal validity of 
randomized trials (Appendix F). It addresses seven specific domains, including sequence 
generation, allocation concealment, blinding of participants and personnel, blinding of 
outcome assessment, incomplete outcome data, selective outcome reporting and other 
issues.
2
 Hartling et al quantified a moderate inter-rater reliability for ‘sequence 
generation’ and fair agreement for all other domains.84  
8. Statistical analysis 
To provide descriptive statistics, we prepared a summary data sheet in Excel from the 
abstracted data. This data sheet included variables such as disease under study, disease 
duration, outcome of interest, risk estimates and confidence intervals; study design, mean 
age, gender distribution, exposure details, study region, accrual start date, publication 
year and variables adjusted in the analysis. We double checked these data against the 
relevant studies to ensure errorless entry of risk estimates and other variables for the 
analysis. We used Comprehensive Meta-analysis Version 2.0 (Inglewood, NJ) for the 
meta-analysis, subgroup analyses and meta-regression analyses. A two-tailed P-value of 
<0.05 was considered to be statistically significant.   
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8.1 Primary analysis 
The primary outcome was a synthesis of cardiovascular events. We considered MTX 
exposure in any form or dose for the primary analysis. Dose-response analysis was 
performed in a secondary analysis. 
When a single study presented stratified analyses according to gender, age group, or other 
risk modifier, where each study group was an autonomous, non-overlapping unit, we used 
a fixed effects model to combine these stratified results into a single study-specific risk 
estimate.
85
 If a study presented independent effect estimates for more than one disease, 
we considered each disease as a separate unit of analysis (a separate study). As our 
outcomes of interest were rare, we considered similarity between different risk estimates 
(odds ratio, relative risk, hazard ratio and incidence rate ratio).
86
 When we found a trial 
with multiple comparison arms, we used data only for the methotrexate user and 
methotrexate non-user (or placebo) arms to calculate risk estimates.  
We calculated relative risk and its confidence interval from the number of events reported 
in randomized controlled trials using the online calculator at 
www.medcalc.org/calc/relative_risk.php. With the exception of randomized trials, we 
took the maximally adjusted risk ratio from each trial for data synthesis. We synthesized 
adjusted risk estimates using DerSimonian and Laird random-effects models and 
computed pooled risk ratios (RR) with 95% confidence intervals for each outcome of 
interest.
87
 The included studies were heterogeneous, representing different autoimmune 
diseases, various study designs, dissimilar geographical areas, patients with diverse risk 
of outcomes, and different methotrexate doses. The random effects model integrates these 
inter-study variations into the analysis, while the fixed effects model does not.    
We assessed statistical heterogeneity across the studies using Higgins’ I2 statistic.88 The I2 
quantity is the proportion of observed variation that is due to real heterogeneity rather 
than chance between studies. The value of I
2
 ranges from 0 to 100%, with zero indicating 
no heterogeneity and larger values indicating progressively higher heterogeneity. Higgins 
et al suggested a practical rule for I
2 
to classify low, moderate or substantial 
heterogeneity.
89
 According to this rule, I
2
 < 25% denotes low heterogeneity; I
2
 = 25% to 
50% denotes moderate heterogeneity, and I
2
 > 50% denotes substantial heterogeneity.  
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8.2 Publication bias 
We used funnel plots to identify publication bias, supplemented by an imputation test.
90
 
Publication bias is one potential cause of funnel plot asymmetry. In the presence of 
publication bias, the funnel plot shows an absence of studies in the extreme areas of 
middle portion as well as missing studies at the bottom of the plot.
91
  
To estimate the impact of publication bias on the effect size and obtain a bias-adjusted 
effect estimate, we used Duval and Tweedie’s trim and fill method.92 This method 
estimates unbiased effect size by removing or adding studies to the funnel plot, making it 
symmetrical. 
8.3 Secondary analysis 
We synthesized studies for the secondary endpoints (all-cause mortality, cardiovascular 
mortality, coronary events, heart failure and stroke) using a random effects model to 
obtain pooled risk ratios. 
8.4 Heterogeneity 
We addressed the issue of heterogeneity for the primary outcome using subgroup 
analyses and meta-regression.  
8.4.1 Subgroup analysis 
We pre-specified the following subgroups for the primary analysis of cardiovascular 
events. We assessed MTX-by-subgroup interactions across the subgroups.  
1. Disease under study: Rheumatoid arthritis carries a higher risk of cardiovascular 
events than any other autoimmune disease. We carried out a subgroup analysis by 
type of autoimmune disease. We explored how the effect size differed between 
rheumatoid arthritis, psoriasis and other diseases (dermatomyositis, polymyositis and 
systemic sclerosis).  
2. Study design: All other things being equal, a prospective cohort study is generally 
considered higher quality evidence than a retrospective cohort or case-control study. 
Using subgroup analyses, we analyzed how the observed effect size differed between 
prospective cohorts, retrospective cohorts and case-control studies for cardiovascular 
events. 
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3. Study region: In this analysis, we examined the association of MTX with 
cardiovascular events between North American and non-North American (European 
and Asian) studies. 
4. Patients with cardiovascular disease: The risk of recurrent cardiovascular events is 
higher in patients with prior cardiovascular disease.
93,94
 We performed a subgroup 
analysis to compare the effect size between studies that excluded patients with prior 
cardiovascular disease and those that did not. 
5. Methotrexate exposure types: We compared the effect of methotrexate in treatment 
initiators versus ever-users on cardiovascular events. 
6. Data source: We performed a subgroup analysis by type of data source. We explored 
how the effect size differed between studies that used administrative databases as a 
data source versus those that used patient medical records. Databases included 
administrative pharmacy records and insurance databases.  
7. Adjustment for DMARDs and other anti-rheumatic medications: To examine the 
independence of the associative risk of methotrexate from concomitant disease-
modifying therapies, we computed the effect size for studies that adjusted for non-
methotrexate DMARDs and other anti-rheumatic medications in their analysis. 
8. Adjustment for cardiovascular risk factors: We explored how the effect size varied 
between studies that adjusted for hypertension, diabetes and dyslipidemia in their 
analysis versus those that adjusted for none of these cardiovascular risk factors.  
9. Adjustment for cardiovascular disease: We carried out a subgroup analysis for studies 
that adjusted for cardiovascular disease in their analysis versus studies that did not.  
10. Adjustment for smoking: We compared the effect size for studies that adjusted for 
smoking versus studies that did not.  
8.4.2 Meta-regression 
We also explored heterogeneity in the primary analysis with respect to several factors 
using a random effects meta-regression on a log risk ratio scale, weighted by the standard 
error of the log risk ratio.
95
 We performed this univariate random effects meta-regression 
using the unrestricted maximum likelihood estimation method. We chose this method 
because it provides conservative confidence interval coverage for the point estimate.
96,97
 
Factors assessed for heterogeneity were: 
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1. Mean age of patients: Due to the differences in cardiovascular risk factor distribution, 
coronary disease is two to five times as common in middle-aged men as women.
98
 
Similarly, age is the strongest predictor of cardiovascular disease.
99
 Risk of 
cardiovascular disease increases with advancing age.
98,100
 We carried out a meta-
regression analysis for mean age distribution across the studies. For each study, we 
collected mean age for the whole cohort. If a study reported median age, we used that 
as the mean age. In case-control studies, where a study reported mean age in cases 
and controls separately, we calculated the weighted average of the means. 
2. Sex distribution: Autoimmune rheumatic diseases are typically more common in 
women than men.
101,102
 Conversely men tend to be at greater risk for cardiovascular 
disease than women.
102
 We collected the proportion of women from each study and 
modelled it as a continuous variable in the meta-regression. 
3. Study accrual (start year): For each study, we collected data on the accrual period. We 
modelled the initial year of the accrual period as a continuous variable. 
4. Publication year: We modelled the year of publication to assess whether the 
association of MTX with cardiovascular events changed over time. 
5. Observation time (in person-years): Several studies have suggested that the 
association between autoimmune disease and cardiovascular disease is sensitive to 
disease duration, study follow-up epoch and cohort type.
103,104
 We obtained a study 
observation period in terms of cumulative person-years exposure for cohort studies. 
Case-control studies were excluded from this analysis.  
6. Quality of studies according to Newcastle-Ottawa Scale (NOS): We assessed quality 
of observational studies using the NOS. The score ranged from 1-9, with greater 
scores representing higher quality. 
7. Analysis adjusted for hypertension, diabetes and dyslipidemia: Obesity, cigarette 
smoking, elevated blood pressure, dyslipidemia and diabetes mellitus are considered 
traditional risk factors for cardiovascular disease.
10
 Using meta-regression, we 
modelled the studies that adjusted for hypertension, diabetes and dyslipidemia versus 
those that adjusted for none of these variables. 
8. Analysis adjusted for smoking: We performed meta-regression among the studies that 
adjusted for smoking versus those that did not. 
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9. Power score of included studies: We calculated the power for the included studies 
using the formula: (1-φ (Cα-Z score) +  φ (-Cα-Z score)), where Cα is the critical 
value of Z associated with significance level α (for α=0.05, Cα=1.96) and Z 
score=effect size/SE. This can be calculated in Excel by: 1- NORMSINV (1.96-Z 
score) + NORMSINV (-1.96-Z score). We used these power scores in the meta-
regression to assess the effects of varying power on effect size.  
We did not have sufficient studies to run a meta-regression by disease duration, as only 
three studies with primary outcome data reported disease duration.    
8.5 Dose-response analysis 
To test for a dose-response relationship, we explored the associative risk of high and low 
dose MTX on cardiovascular events. We considered the cut-point for high and low dose 
MTX as defined by each study. We performed separate syntheses for high and low dose 
MTX.      
9. Overall quality of the evidence 
We used the GRADE approach to rate the overall quality and strength of the estimated 
association with cardiovascular events.
105
 Two investigators (AS and DH) independently 
assessed the quality of the evidence. We presented the results of this assessment in a 
GRADE ‘summary of findings’ table. We then reported the overall GRADE score.    
10. Presentation of results 
We reported this systematic review according to the PRISMA guidelines. A flow chart 
was presented for the study identification and selection process. We summarized the 
study characteristics, disease under study, outcome characteristics, exposure details, and 
summary statistics in tabular format. We presented forest plots for the overall association 
of MTX with primary as well as secondary outcomes. We used funnel plots with trim-
and-fill analyses to assess for publication bias.  
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11. Tables 
 
Table 1. Search terms used in the Ovid Medline search strategy 
Topic MeSH terms Key words 
Autoimmune 
diseases 
Autoimmune Diseases, 
Rheumatic diseases,  
Arthritis, Rheumatoid 
Psoriasis 
Myositis 
Polymyositis 
Dermatomyositis 
Lupus Erythematosus, Systemic 
Multiple Sclerosis 
Sjogren's Syndrome 
Pemphigoid, Bullous 
Inflammatory Bowel Diseases 
Myelitis, Transverse 
Scleroderma, Systemic 
Myasthenia Gravis 
Anti-Neutrophil Cytoplasmic 
Antibody-Associated Vasculitis 
Polyarteritis nodosa 
Takayasu arteritis 
Autoimmune, rheumatic, 
rheumatoid, psoriatic, arthritis, 
psoriasis, polymyositis, 
dermatomyositis, inflammatory 
myopathies, systemic lupus 
erythematosus, SLE, multiple 
sclerosis, Sjogren’s, bullous 
pemphigoid, inflammatory 
bowel disease, ulcerative colitis, 
Crohn’s, IBD, systemic 
sclerosis, myasthenia gravis, 
Wegener’s granulomatosis, 
microscopic polyangiitis, 
polyarteritis, allergic and 
eosinophilic granulomatosis, 
Churg-strauss syndrome, 
ANCA, anti-neutrophil 
cytoplasmic antibody associated 
vasculitis 
Methotrexate Methotrexate methotrexate, amethopterin, 
MTX and all possible trade 
names of methotrexare 
identified from online search 
and EMBASE database 
Mortality 
outcomes 
mortality, cause of death, fatal 
outcome, hospital mortality, 
death, sudden cardiac death, 
sudden death, death certificate, 
life expectancy, life tables, vital 
statistics 
Mortality, death, died, die, fatal, 
life expectancy, life table, Cox 
model, Kaplan Meier 
Cardiovascular 
outcomes 
cardiovascular diseases 
cerebrovascular diseases 
cardiovascular, cerebrovascular, 
cardiac, myocardial, heart, 
coronary, morbidity, stroke, 
IHD, CHF, CVA, CVD, MI, 
CHD, CAD, infarct, arrest, 
disease, ischemic, failure, event, 
bypass, revascularization, 
disorders 
Abbreviations-IHD: Ischaemic heart disease, CAD: Coronary artery disease, CHD: Coronary heart 
disease, CHF: Congestive heart failure, CVA: Cerebrovascular accident, CVD: Cardiovascular disease, MI: 
Myocardial infarction. 
28 
 
 
 
Table 2. Study inclusion and exclusion criteria 
 Inclusion criteria Exclusion criteria 
Study design Cohort studies, case-control studies, 
randomized controlled trials 
Cross-sectional studies, letters, 
commentaries, editorials, case 
reports, reviews, cross-over 
trials, in vitro studies 
Disease under 
study 
Any of the autoimmune diseases listed 
in the text 
Studies without one of the 
listed autoimmune diseases 
Outcomes of 
interest 
- Studies reporting cardiovascular 
events, cardiovascular mortality and/or 
all-cause mortality 
- Trials reporting mortality or CV 
events in MTX users and a placebo 
group 
Studies without any of these 
endpoints 
Country of 
origin 
Any  
Study 
duration 
Any  
Language English articles Non-English articles 
Comparison - Studies comparing outcome of 
interest in MTX users versus non-
users or placebo group, using 
multivariate regression to adjust for 
potential confounders 
- Study using topical agents or 
phototherapy as a control group  
- Studies assessing exposure 
other than MTX such as anti-
TNF agents, other 
conventional DMARDs, 
glucocorticoids, cytotoxic and 
non-cytotoxic agents 
- Studies comparing outcome 
of interest in MTX users 
versus an active control group 
 
Risk 
measures 
- Observational studies reporting any 
of the following adjusted risk 
measures along with its 95% 
confidence interval or standard error 
or p-value: incidence rate ratio, odds 
ratio, relative risk, hazard ratio. 
- Trials reporting binary event data  
- Observational studies 
reporting unadjusted numbers 
or percentages of events 
without adjusted relative risk 
measures 
- Trials without binary event 
data 
Other 
consideration 
In case of multiple publications from the same patient population, we 
selected the study with the largest sample size 
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Chapter 3: Results 
 
1. Citation screening 
We initially identified a total of 14,042 potential records from bibliographic databases 
and grey literature (Figure 3). We removed 563 duplicate records. We then screened 
13,479 records by title, abstract and keywords to identify relevant studies. We excluded 
13,292 irrelevant records. What remained were 187 potentially relevant records, for 
which we retrieved full text to better assess their eligibility. 
We excluded 157 studies for the reasons described in Figure 3. A total of 30 studies met 
all selection criteria and were included in the meta-analysis. The kappa statistic for inter-
rater agreement was 0.77, indicating substantial agreement.  
2. INCLUDED STUDIES 
2.1 Study characteristics 
Appendix G presents characteristics of the included studies. There were 20 cohort 
studies, 7 case-control studies and 3 randomized controlled trials. The majority of the 
studies were from North America (n=17); a number were from Europe (n=10) and 
relatively few from Asia (n=3). The earliest published study was by van Den Hoogen et 
al in 1996 and the latest one was by Norton et al in 2014.
106,107
 Our review included a 
total of 122,113 patients; 98,295 from cohort studies, 23,400 from case-control studies 
and 418 from randomized trials.  
2.2 Characteristics of disease 
As per Appendix H, the majority of studies examined the effect of MTX in patients with 
RA (n=21). Other autoimmune diseases studied were psoriasis (n=3), systemic sclerosis 
(n=3), inflammatory polyarthritis (n=1), and myositis (n=1). Prodanowich et al studied 
patients with RA as well as psoriasis.
108
 Two studies, Chin et al and Wu et al, included 
patients with psoriatic arthritis along with psoriasis.
67,109
 Among the studies using RA 
patients, 11 studies used American College of Rheumatology criteria for RA diagnosis, 
three studies used ICD-9 diagnosis codes and four studies used rheumatologist diagnosis 
as a diagnostic criterion. Three studies did not specify diagnostic criteria for the disease 
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under study.
68,107,110
 Only 15 studies specified disease duration, which ranged from a 
maximum of 12 months in Ajeganova et al to a mean of 14.5 years in Davis et al.
63,75
 
2.3 Exposure characteristics 
Appendix I describes the exposure characteristics for MTX. The included studies used 
differing definitions for MTX exposure. Use of MTX for more than six months during 
the observation period was considered MTX exposure in four studies.
63,66,111,112
 Choi et al 
used the intention-to-treat concept for defining MTX therapy.
113
 MTX-user comparisons 
included ever-users versus never-users (n=13), current-users versus non-users (n=8) and 
initiators versus non-initiators (n=8). All randomized trials compared MTX users with a 
placebo group.
106,114,115
 In these trials, we categorized MTX exposure as initiators versus 
non-initiators. Exposure status was not clear in Mantel et al.
110
 The majority of studies 
extracted MTX exposure data from patient medical records (n=16); whereas others used 
administrative databases (n=11) or self-administered questionnaires (n=3) to capture 
MTX exposure.  
2.4 Outcome characteristics 
Outcome characteristics are described in Appendix J. Most of the studies reported 
composite cardiovascular events (n=7).
63,70,75,108,116-118
 Others reported myocardial 
infarction (n=5), acute coronary syndrome (n=1), coronary artery disease (n=2), stroke 
(n=4), and heart failure (n=2). Eleven studies reported all-cause mortality and only 3 
studies reported cardiovascular mortality. Choi et al and Goodson et al assessed both all-
cause and cardiovascular mortality.
111,113
 Ajeganova et al and Davis et al evaluated both 
cardiovascular events and all-cause mortality.
63,75
 All randomized controlled trials 
reported mortality as an adverse event.  
The following are study-specific definitions for cardiovascular events in each of seven 
studies reporting the primary outcome. 
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Study name Cardiovascular events 
Ajeganova et al., 2013
63
 
Fatal or non-fatal myocardial infarction (MI), angina 
pectoris, coronary artery bypass grafting (CABG) or 
percutaneous coronary intervention (PCI), peripheral 
artery disease (PAD), vascular surgery, ischemic stroke, 
transient ischemic attack (TIA) 
Davis et al., 2013
75
 Fatal or non-fatal MI, stroke, PCI, CABG 
Gonzalez-Gay et al., 2007
116
 
Ischemic heart disease (IHD), acute coronary syndrome 
(ACS), MI, heart failure, cerebrovascular accident 
(CVA), peripheral arteriopathy 
Meek et al., 2014
70
 
Fatal or non-fatal MI, Percutaneous transluminal coronary 
angioplasty (PTCA), CABG, angina pectoris, acute heart 
failure, CVA, death due to cardiac causes and sudden 
death 
Prodanowich et al., 2005
108
 Cardiovascular disease, cerebrovascular disease, 
atherosclerosis 
Tisseverasinghe et al., 
2009
118
 Stroke, IHD, PAD, MI 
van Halm et al., 2006
117
 MI, CABG, PTCA, ischemic abnormality on ECG, CVA, 
TIA, carotid endarterectomy and PAD 
 
2.5 Number of events 
There were a total of 4380 cardiovascular events (primary endpoints), 958 strokes, 612 
diagnoses of heart failure, 2081 myocardial infarctions, 29 episodes of ischemic heart 
disease, 1829 deaths and 186 cardiovascular deaths. Three studies presented only relative 
risk measures without reporting the number of events.
65,107,110
 Prodanowich et al reported 
the highest number of cardiovascular events; Wasko et al reported the highest number of 
all-cause deaths; and Goodson et al reported the highest number of cardiovascular 
deaths.
108,111,119
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2.6 Characteristics of studies reporting primary outcome (n=7) 
Seven studies included cardiovascular events as the outcome. Prodanowich et al studied 
the effect of MTX in RA and psoriasis patients separately; therefore these were 
considered as two separate studies. Thus, there were a total of eight studies in the meta-
analysis for the primary outcome, with an aggregate sample size of 17,796 patients.  
2.7 Results of individual studies 
Results from individual studies are presented in Table 3 at the end of this chapter. Most 
of the studies (n=16) used hazard ratios (95% confidence intervals) to report the effect of 
MTX on the outcomes; two studies used rate ratios, two studies used relative risks, one 
study reported incidence rate ratio and six studies used odds ratios. From the number of 
events reported in three randomized trials, we calculated the relative risk and 95% 
confidence interval.   
A study by Meek et al
70
 presented a hazard ratio of 3.436 (95% CI: 1.553, 7.576) for the 
protective effect of MTX against incident first cardiovascular event in RA patients. To 
interpret this hazard ratio as a risk of the first cardiovascular event in MTX users versus 
non-users, we took the reciprocal of it. We calculated the standard error from 95% 
confidence interval, inverted it and re-calculated the 95% confidence interval to be used 
in the meta-analysis.  
Chin et al reported two outcomes: cerebrovascular and cardiovascular events.
67
 To avoid 
doubling the control group by combining these outcomes into a single measure, we only 
considered cerebrovascular outcomes for the analysis on stroke.  
Troelsen et al assessed ischemic heart disease (IHD) and myocardial infarction (MI) as 
two separate outcomes.
120
 There was a chance of overrepresentation of the study if we 
had combined these two outcomes in a single measure. As MI is a subset of IHD, and 
IHD is a more diverse outcome, we used only IHD in this meta-analysis.   
Walfe and Michaud presented risk estimates for first observed MI and all MI 
separately.
112
 We considered all MI as the outcome of interest. 
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3. PRIMARY ANALYSES 
3.1 Cardiovascular events 
Figure 4 gives the associations from individual studies and the overall pooled estimate for 
the association of MTX with cardiovascular events, analysed using random effects meta-
analysis. MTX was significantly associated with a decreased risk of cardiovascular events 
with a pooled risk ratio of 0.75 (95% CI: 0.65, 0.86).  
The greatest effect size was observed in a study by Meek et al with a risk ratio of 0.29 
(95% CI: 0.13, 0.65) and the smallest effect in Tisseverasinghe et al (RR: 0.90, 95% CI: 
0.33, 2.49). Although the individual study effects were numerically protective, three 
studies presented statistically non-significant effects.
116-118
 I
2
 for the overall pooled 
estimate was 11%, indicating minimal heterogeneity.  
4. SECONDARY ANALYSES 
4.1 All-cause mortality 
MTX was associated with significantly decreased all-cause mortality with a pooled risk 
ratio of 0.60 (95% CI: 0.48, 0.76). In Figure 8, we have presented separate analyses for 
cohort studies and randomized trials. The overall effect was statistically significant in 
cohort studies (RR: 0.60, 95% CI: 0.47, 0.76), while non-significant in randomized trials 
(RR: 0.69, 95% CI: 0.24, 2.00). There was moderate heterogeneity for the overall pooled 
effect estimate with an I
2
 of 45%.  
4.2 Cardiovascular mortality 
Only three studies examined the association of MTX with cardiovascular 
mortality.
111,113,116
 As shown in Figure 9, MTX was associated with reduced 
cardiovascular mortality. The overall pooled risk ratio was 0.45 (95% CI: 0.26, 0.80). I
2
 
for the pooled estimate was 33%, indicating moderate heterogeneity.  
4.3 Specific cardiovascular events (as a secondary analysis) 
MTX was associated with a lower risk of coronary events with a pooled risk ratio of 0.78 
(95% CI: 0.67, 0.91), and a non-significantly lower risk of heart failure (RR: 0.61, 95% 
CI: 0.32, 1.19) and stroke (RR: 0.67, 95% CI: 0.42, 1.09) (Figure 11).  
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5. Subgroup analysis for cardiovascular events 
Table 4 reports the results from subgroup analyses. Tests of interaction across the 
specified subgroups were all non-significant at the p<0.05 level of significance.  
6. Meta-regression for cardiovascular events 
We carried out univariate random effects meta-regression for the pre-specified variables. 
The results are shown in Table 5. All predictors were non-significant in the analysis. 
7. Dose-response analysis 
A total of three studies reported an MTX-dose analysis for cardiovascular events.
69,108,117
 
In Figure 6, we compared the effect of high- and low- cumulative dose MTX. Low 
cumulative dose MTX showed a more sizeable reduction in cardiovascular events (RR: 
0.61, 95% CI: 0.51, 0.74) compared to the association for high cumulative dose MTX 
(RR: 0.88, 95% CI: 0.78, 0.99).  The test of significance across dose was statistically 
significant (p-value: 0.001). 
8. Publication bias 
We assessed publication bias using funnel plots, and its impact using Duval and 
Tweedie’s trim and fill method (Figures 7 for cardiovascular events and Figure 10 for all-
cause mortality).  
For cardiovascular events, the method imputed two studies to the right of the null line to 
make the plot symmetrical. The publication bias adjusted risk ratio was almost the same 
as the observed risk ratio: RR 0.75 (95% CI: 0.65, 0.86) versus RR 0.76 (95% CI: 0.63, 
0.92). Similarly, for all-cause mortality, the observed risk ratio remained unchanged after 
adjustment for publication bias. 
9. Methodological quality of included studies 
We assessed the methodological quality of observational studies using the Newcastle-
Ottawa-Scale. Appendix L and M displays the score of NOS for cohort and case-control 
studies respectively. The cohort studies’ NOS score ranged from 6 to 9. Median (IQR) of 
the NOS score for cohort studies was 8 (1). All seven case-control studies had an NOS 
score from 6 to 8.  Median (IQR) of the NOS score for case-control studies was 7 (0.5). 
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Among the studies reporting the primary outcome, median (IQR) of the NOS score was 8 
(1.5). 
We used the Cochrane risk of bias tool to assess the methodological quality of 
randomized controlled trials. In Appendix N, we have presented the review author’s (AS) 
judgement for each quality item.  
10. Overall quality of evidence 
We used the GRADE ‘summary of findings’ table to present the overall quality of 
evidence for each outcome.
105
 Table 7 represents the rating of the evidence. In the 
GRADE system, randomized controlled trials are graded as high-quality and 
observational studies as low-quality evidence. However, if there is evidence of a large 
effect size, dose response gradient or implausible confounding, the quality of 
observational studies should be rated up.
105
 
All 8 studies reporting the primary outcome were observational studies. We rated this 
evidence as moderate evidence due to the reported dose response gradient for low and 
high dose MTX. For all-cause mortality and coronary endpoints, the evidence was 
labelled as very low-quality as there was moderate heterogeneity with I
2
 of 45% and 30% 
respectively. The evidence for cardiovascular mortality was rated very low-quality 
evidence due to inconsistency (I
2
: 33%) and suspected publication bias. For stroke, the 
evidence has both imprecision and inconsistency, and thus was labelled as very low grade 
evidence. Results from heart failure studies were assessed as inconsistent and imprecise, 
resulting in very low grade evidence.    
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11. Tables and Figures 
 
 
 
  
Records identified through 
database searching 
(n=13809) 
 
Additional records identified 
through other sources 
(n=233) 
Database updates = 194 
Snowballing = 39 
Total records identified 
(n=14042) 
Duplicate records removed 
(n=563) 
Total records screened for titles, 
abstracts and keywords  
(n=13479) 
Records excluded as irrelevant 
(n=13292) 
Full text studies assessed for 
eligibility in duplicate 
(n=187) 
Full text studies excluded (n=157) 
 Non-English language (8) 
 Duplicate data or insufficient data 
(9) 
 Case-reports, letters, commentaries, 
or editorials (37) 
 Cross-sectional design or cross-
over RCT (3) 
 Active comparators (7) 
 Unrelated disease population (3) 
 Studies without relevant outcomes 
(8) 
 Studies with no outcome data for 
MTX (55) 
 No assessment of an independent 
effect of MTX on outcomes (18) 
 No statistical measures presented 
(1) 
 Studies with unadjusted data (8) 
  
Studies included in quantitative 
synthesis 
(n=30) 
 
Studies included in 
quantitative synthesis 
(n=30) 
Figure 3. Screening and selection process for studies 
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Table 3. Results of individual studies 
Study Observation time Outcome Number of 
events 
Effect 
measure 
Risk estimates 
(95% CI) 
Variables adjusted for 
Ajeganova 
et al., 2013 
9405 
person-years 
Cardiovascular events 
All-cause mortality 
177 
151 
HR 
0.72 (0.53 - 0.99) 
0.99 (0.71 - 1.38) 
Age, sex, smoking status at inclusion, 
HTN, DM,  hyperlipidemia 
Bernatsky 
et al., 2005 
51301 
person-years 
CHF requiring 
hospitalization 
520 Rate ratio 0.80 (0.60 - 1.00) 
Age, sex, cohort, comorbidities, current 
DMARDs, use of NSAIDs, COX-2 
inhibitors, glucocorticoids 
Bozaite-
Gluosniene 
et al.,2011 
Not specified CAD Not specified HR 0.54 (0.37 -  0.77) 
Age, sex, HTN, hyperlipidemia, DM,  
RF, BMI, blood pressure, LDL, ESR, 
Hydroxychloroquine, MTX, corticosteroid 
and NSAID use 
Chiang et 
al., 2013 
Median 
4.7 years 
Ischemic stroke 86 HR 1.47 (0.64 - 3.42) 
Age, sex (male), HTN, DM, dyslipidemia, 
chronic kidney disease, CAD and AF 
Chin et al., 
2013 
Cerebrovascular 
event: psoriasis: 
3428.5 ± 11.2 and 
PsA: 3235.2 ± 60.4 
days, CV events: 
psoriasis:3275.0 ± 
14.5 and PsA: 
3085.1 ± 70.5 days 
Cerebrovascular events 
Cardiovascular events 
406 
688 
HR 
0.45 (0.23 - 0.85) 
0.48 (0.29 - 0.81) 
Age, sex, HTN, diabetes,  
dyslipidemia and phototherapy 
Choi et al., 
2002 
91007 
person-months 
All-cause mortality 
Cardiovascular mortality 
191 
84 
HR 
0.40 (0.20 - 0.80) 
0.30 (0.20 - 0.70) 
Age, sex, RF, calendar year, disease 
duration, smoking, education, HAQ score, 
PtGA, joint counts, ESR, prednisone use, 
no. of other DMARDs 
Cohen et 
al., 2001 
24 months All-cause mortality 3 RR 1.34 (0.12 - 14.7)  
Davis et al., 
2013 
3743 
person-years 
Cardiovascular events 
All-cause mortality 
97 
252 
HR 
0.66 (0.44 - 1.00) 
0.75 (0.58 - 0.97) 
Multiple patient demographic  
and RA severity 
Edwards et 
al., 2008 
Not specified MI 966 IRR 0.86 (0.74 – 1.00) Age, sex, BMI, HTN, DM, smoking 
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Study Observation time Outcome Number of 
events 
Effect 
measure 
Risk estimates 
(95% CI) 
Variables adjusted for 
Gonzalez-
Gay et al., 
2007 
Mean (IQR): 
13.4, (10-16) years 
Cardiovascular events 
Cardiovascular mortality 
39 
17 
HR 
0.86 (0.39 - 1.80) 
0.86 (0.28 - 2.69) 
Age at disease onset and sex 
Goodson et 
al., 2008 
10 years 
All-cause mortality 
Cardiovascular mortality 
203 
85 
OR 
0.59 (0.35 - 0.97) 
0.53 (0.25 - 1.14) 
Age, sex, joint counts, RF, nodules, RA, 
NSAIDs, steroids, CRP, smoking, HAQ, 
number of comorbid medications used 
Lan et al., 
2012 
Not specified Cerebrovascular event 399 HR 0.50 (0.27 - 0.92) HTN, DM,  dyslipidemia, age and sex 
Levesque et 
al., 2013 
2,386.4 
person-years 
(MTX exposure) 
MI 53 HR 0.85 (0.40 - 1.84) 
Age, sex, history of MI, DM, HTN, 
hyperlipidemia and use of corticosteroid 
Mantel et 
al., 2014 
Average 
5.3 years 
Acute coronary syndrome Not specified OR 1.10 (0.60 – 2.20) 
Age, sex, year of RA diagnosis and study 
center* 
Meek et al., 
2014 
1380 
person-years 
Cardiovascular event 29 HR 0.29 (0.13, 0.65) 
CV risk factors, inflammatory parameters, 
disease duration, presence of IgM RF 
and/or anti-CCP antibodies, use of anti-
inflammatory immunosuppressive therapy 
Mikuls et 
al., 2011 
2314 
person-years 
All-cause mortality 138 HR 0.63 (0.42 - 0.96) Age, race, BMI, comorbidities 
Myasoedov
a et al., 
2011 
7692 
person-years 
Heart failure 92 HR 0.40 (0.20 – 0.80) 
Age, sex, calendar year, CV risk factors, 
CHD, RF positivity, RA duration, ESR 
and severe ExRA 
Nadareishvi
li et al., 
2008 
Mean (IQR): 
3.9 (2.0 – 6.0) 
Years 
Ischemic stroke 67 cases OR 0.77 (0.39-1.54) 
(Age, sex, calendar time)* 
HAQ, total joint replacement, RA 
duration, low dose aspirin, comorbidity 
index (0-9 for 11 comorbidities) 
Norton et 
al., 2014 
Not specified All-cause mortality Not specified HR 0.40 (0.25 - 0.64) 
Demographic and clinical features at 
baseline, confounding by indication of 
treatment effect 
Pope et al., 
2001 
Median 
1.5 years 
All-cause mortality 10 RR 0.44 (0.12-1.56)  
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Study Observation time Outcome Number of 
events 
Effect 
measure 
Risk estimates 
(95% CI) 
Variables adjusted for 
Prodanowic
h et al., 
2005 
Not specified 
Cardiovascular events 
(psoriasis) 
Cardiovascular events 
(RA) 
1869 
 
2017 
RR 
0.73 (0.55-0.98) 
 
0.83 (0.71-0.96) 
Age, sex, DM, HTN, dyslipidemia, other 
medications (FA, B6, B12) 
Suissa et 
al., 2006 
166194  
person-years 
MI 558 Rate ratio 0.81 (0.60 - 1.08) 
Age, DMARDs, other anti-RA drugs, 
IHD, PAD, other CVD, DM, respiratory 
illness 
Tisseverasi
nghe et al., 
2009 
Mean (SD): 
4 (3.7) years 
Cardiovascular events 80 RR 0.90 (0.30 – 2.30) 
Comorbidities, steroid, NSAID, Cox-2 
inhibitors, immunomodulators, data source 
for MI diagnosis, h/o coagulopathy and/or 
exposure to aspirin, warfarin or Low 
molecular weight heparin 
Troelsen et 
al., 2007 
1799 
person-years 
IHD 
MI 
29 
12 
HR 
0.60 (0.20 – 1.80) 
0.70 (0.10 – 5.00) 
Age and sex 
van den 
Hoogen et 
al., 1996 
48 weeks All-cause mortality 3 RR 1.41 (0.14 -13.85)  
van Halm et 
al., 2006 
5649 
person-years 
Cardiovascular events Cases: 72 OR 0.47 (0.07-3.23) 
Age, sex, smoking, RA duration, HTN, 
DM, hypercholesterolemia 
Wasko et 
al., 2013 
40,722 
patient-years 
All-cause mortality 666 HR 0.30 (0.09 – 1.03) 
Age, education level, sex, BMI, HAQ 
score, ethnicity, RA duration, HTN, CAD, 
DM, stroke, prednisone, TNF inhibitors, 
non-MTX DMARDs, NSAIDs, and cox-2 
inhibitors and other comorbidities 
Wolfe and 
Michaud, 
2008 
Mean (IQR): 
3 (0.5 – 8.5) 
Years 
MI (All) 
MI (First MI) 
283 
223 
OR 
 
0.90 (0.70 - 1.20) 
0.90 (0.70 - 1.20) 
 
Education, ethnicity, smoking, DM, 
aerobic exercise, HTN, comorbidity index 
from 11 present and past conditions, low-
dose aspirin, BMI, baseline MI status, 
PAS score, joint replacement status, RA 
duration 
Wolfe et al., 
2003 
88063 
person-months 
All-cause mortality 212 OR 0.51 (0.37-0.72) 
Age, sex, HAQ score, MTX (time-
varying), RA and disease factors 
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Study Observation time Outcome Number of 
events 
Effect 
measure 
Risk estimates 
(95% CI) 
Variables adjusted for 
Wu et al., 
2012 
42424 
person-years 
MI 221 HR 0.52 (0.31-0.85) 
Age, sex, person-years among the cohorts, 
CV risk factors, medications that are 
known to reduce MI risk 
Abbreviations: HTN: hypertension, DM: diabetes mellitus, BMI: Body Mass Index, RF: rheumatoid factor, LDL: low density lipoprotein, ESR: erythrocyte 
sedimentation rate, NSAID: non-steroidal anti-inflammatory drug, CAD: coronary artery disease, AF: atrial fibrillation, HAQ: Health Assessment Questionnaire, PtGA: 
patient global assessment of disease activity, IRR: incident rate ratio, CRP: C-reactive protein, ExRA: extra-articular manifestations of RA, RCT: randomized controlled 
trials 
* Variables matched in study design 
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Figure 4. Effect of MTX on primary outcome (cardiovascular events) 
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Table 4. Subgroup analysis for the primary outcome (cardiovascular events) 
Subgroup 
# of 
studies 
Risk ratio 
(95% CI) 
I
2
 
Q statistics  
(P-value) 
(Test of 
interaction) 
Disease  
RA 6 0.72 (0.58, 0.89) 34.71 
0.17 (0.92) Psoriasis 1 0.73 (0.48, 1.10) 0.00 
Others (PM, DM) 1 0.90 (0.31, 2.60) 0.00 
Study design 
Prospective cohort 4 0.66 (0.51, 0.84) 37.09 
1.60 (0.45) Retrospective cohort 2 0.80 (0.67, 0.96) 0.00 
Case-control 2 0.78 (0.31, 1.90) 0.00 
Study region 
America 4 0.79 (0.68, 0.91) 0.00 
1.27 (0.26) 
Europe 4 0.66 (0.50, 0.87) 38.66 
Study excluded patients with history of CVD 
Yes 6 0.75 (0.63, 0.88) 30.91 
0.10 (0.75) 
No 2 0.69 (0.46, 1.05) 0.00 
MTX exposure type 
Initiators 2 0.56 (0.39, 0.80) 68.59 
3.27 (0.07) 
Ever-users 6 0.79 (0.70, 0.90) 0.00 
Data source for MTX exposure 
Database 3 0.71 (0.54, 0.93) 0.00 
0.13 (0.72) 
Medical records 5 0.75 (0.62, 0.91) 42.69 
Adjusted for DMARDs/other anti-rheumatic medications in the analysis 
Yes 2 0.45 (0.24, 0.84) 65.80 
2.88 (0.09) 
No 6 0.78 (0.70, 0.88) 0.00 
Adjusted for hypertension, diabetes and dyslipidemia in the analysis 
Yes 6 0.74 (0.63, 0.88) 31.02 
0.06 (0.80) 
No 2 0.71 (0.47, 1.05) 0.00 
Adjusted for CVD in the analysis (omitted studies which excluded patients with CVD) 
Yes 1 0.90 (0.32, 2.54) 0.00 
0.14 (0.71) 
No 7 0.74 (0.63, 0.86) 22.93 
Adjusted for smoking in the analysis 
Yes 3 0.63 (0.48, 0.85) 54.13 
1.98 (0.16) 
No 5 0.80 (0.70, 0.90) 0.00 
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Table 5. Meta-regression results for primary outcome (cardiovascular events) 
Covariate 
Estimated β 
coefficient 
(95% CI) 
p- Value τ2 
Mean age (years) -0.008 (-0.065, 0.048) 0.77 0.000 
% Female -0.002 (-0.007, 0.002) 0.28 0.000 
Accrual start (year) -0.030 (-0.071, 0.010) 0.15 0.000 
Publication year -0.028 (-0.061, 0.005) 0.10 0.000 
Observation time (person-years) 0.000 (-0.000, 0.000) 0.31 0.000 
Quality of studies according to NOS 0.072 (-0.062, 0.208) 0.29 0.000 
Analysis adjusted for HTN, DM and 
dyslipidemia 
0.101 (-0.279, 0.483) 0.60 0.000 
Analysis adjusted for smoking -0.225 (-0.539, 0.088) 0.16 0.000 
Analysis adjusted for hypertension 0.101 (-0.279, 0.483) 0.60 0.000 
Analysis adjusted for diabetes 0.101 (-0.279, 0.483) 0.60 0.000 
Power score of included studies 0.708 (-0.002, 1.419) 0.05 0.000 
 
 
 
Figure 5. Association of MTX with the primary outcome by study design 
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Figure 6. MTX dose response analysis for the primary outcome (cardiovascular 
events) 
 
(Low cumulative MTX dose: cumulative dose <1.56 g (in Lan et al), or less than 
median dose (in Prodanowich et al); High cumulative MTX dose: cumulative dose 
>1.56 g (in Lan et al), or more than median dose (in Prodanowich et al and van Halm et 
al)) 
 
 
Figure 7. Funnel plot: Effect of MTX on primary outcome (cardiovascular events) 
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Figure 8. Effect of MTX on all-cause mortality (secondary outcome) 
 
 
 
Figure 9. Effect of MTX on cardiovascular mortality (secondary outcome) 
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Figure 10. Funnel plot: Effect of MTX on all-cause mortality (secondary outcome) 
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Figure 11. Effect of MTX on cardiovascular diseases (secondary outcome) 
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Table 6. Summary table of effect of MTX on different outcomes 
Outcome # of studies 
Random effects 
RR (95% CI) 
I-squared 
Primary outcome    
Cardiovascular events 8 0.75 (0.65, 0.86) 11% 
Secondary outcomes    
All-cause mortality 11 0.60 (0.48, 0.76) 41% 
Cardiovascular 
mortality 
3 0.45 (0.26, 0.80) 33% 
Coronary endpoints 8 0.78 (0.67, 0.91) 30% 
Stroke 4 0.67 (0.42, 1.09) 48% 
Heart failure 2 0.61 (0.32, 1.19) 70% 
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Table 7. Summary of findings 
Question:  Is methotrexate associated with a lower risk of cardiovascular events in patients with autoimmune disease? 
Population:  Patients with autoimmune disease (RA, psoriasis, psoriatic arthritis, systemic sclerosis, myositis, inflammatory polyarthritis)  
Intervention:  MTX 
Comparison: MTX non-user group 
Outcome:  Cardiovascular events, all-cause mortality, cardiovascular mortality, coronary endpoints, and stroke 
Outcome 
Risk of 
bias 
Inconsistency Indirectness Imprecision 
Publication 
bias 
Number of 
participants 
(studies) 
Relative 
effect 
(95% CI) 
Quality of 
evidence 
(GRADE) 
Cardiovascular 
events 
likely1 
no serious 
inconsistency2 
no serious 
indirectness3 
no serious 
imprecision4 
not likely5 
17796 
(8) 
0.75 
(0.65, 0.86) 
moderate1,2,3,4,5,6 
All-cause 
mortality 
likely7 inconsistency8 
no serious 
indirectness3 
no serious 
imprecision4 
not likely5 
15160 
(11) 
0.60 
(0.48, 0.76) 
very low3,4,5,7,8  
Cardiovascular 
mortality 
likely9 inconsistency10 
no serious 
indirectness3 
no serious 
imprecision11 
strongly 
suspected12 
2345 
(3) 
0.45 
(0.26, 0.80) 
very low3,9,10,11,12 
Coronary 
endpoints 
likely14 inconsistency13 
no serious 
indirectness3 
no serious 
imprecision4 
not likely5 
66248 
(8) 
0.78 
(0.67, 0.91) 
very low3,4,5,13,14 
Stroke likely17 inconsistency15 
no serious 
indirectness3 
 
imprecision16 
not likely5 
18182 
(4) 
0.67 
(0.42, 1.09) 
very low3,5,15,16,17 
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Heart failure likely18 inconsistency19 
no serious 
indirectness3 
 
imprecision16 
Undetected20 
6515 
(2) 
0.61 
(0.32, 1.19) 
very 
low3,16,18,19,20 
 
 
1
median score of Newcastle-Ottawa scale was 8 (interquartile range (IQR): 1.5), however, all included studies were observational 
2
overlaping CIs, non-significant p for heterogeneity and I
2
: 11%, suggesting minimal heterogeneity 
3
patients (autoimmune disease), intervention (MTX) and outcome were consistent 
4
CI of the overall effect does not include null value. Also, a number of events and total patients were large enough to achieve adequate power 
5publication bias adjusted estimate didn’t change considerable from the observed estimate 
6
dose-response gradient was observed in the subgroup analysis, showing higher effect with low dose MTX  
7
median score of New-castle-Ottawa scale was 9 (IQR: 1.25) for cohort studies; and the overall assessment for RCTs suggests a low risk of bias, however, the 
majority of included studies were observational 
8
significant p value for heterogeneity and I
2
: 45%, suggesting moderate heterogeneity 
9
median score of New-castle-Ottawa scale was 8 (IQR: 0.5), however, all included studies were observational 
10
non-overlapping CIs, non-significant p value for heterogeneity and I
2
:33%, suggesting moderate heterogeneity 
11
CI of the overall estimate does not include null value. A total number of events was 433 with >30% of relative risk reduction 
12
publication bias adjusted estimate differed from the observed estimate 
13
non-overlapping CIs with I
2
: 30% 
14
median score of New-castle-Ottawa scale was 8 (IQR: 1.25), however, all included studies were observational 
15
non-overlapping CIs, non-significant p value for heterogeneity and I
2
:48%, suggesting moderate heterogeneity 
16
wide CI for the overall estimate which includes null value; and point estimate showed an extreme benefit 
17
median score of New-castle-Ottawa scale was 8 (IQR: 0), however, all included studies were observational 
18
median score of New-castle-Ottawa scale was 8 (IQR: 1), however, all included studies were observational 
19
non-overlapping CIs and I
2
:70%, suggesting substantial heterogeneity 
20
publication bias could not be tested for n = 2 studies for heart failure 
 
 
 
51 
 
 
 
Chapter 4: Discussion 
 
1. Summary of findings 
Our systematic review and meta-analysis suggests that MTX is associated with a 25% 
reduction in cardiovascular events in patients with autoimmune disease. GRADE 
assessment labelled this as moderate evidence, meaning that the true effect is close to the 
observed effect but there is a possibility that it is considerably different. In our search, we 
included all autoimmune diseases for which MTX is recommended as therapy. However, 
we found studies in RA, psoriasis, psoriatic arthritis and myositis only. The statistical 
heterogeneity for the pooled effect estimate was 11%. We explored this heterogeneity in 
subgroup analyses and meta-regression according to a variety of patient and study 
characteristics. None of the subgroup analyses or meta-regression predictors were 
statistically significant. 
A similar direction of effect was observed for all-cause mortality. MTX was associated 
with a 40% reduction in all-cause mortality in patients with RA, systemic sclerosis and 
inflammatory polyarthritis. This finding was accorded very low GRADE evidence. We 
included three RCTs reporting mortality as an adverse event in the synthesis of this effect 
estimate. These trials were of short duration and small sample size, so the confidence 
intervals for individual trials as well as the pooled effect were wide. These trials were 
underpowered for reporting mortality outcomes. Therefore, this result should be treated 
with caution. The pooled effect from cohort studies also indicated 40% lower risk for 
mortality with a narrow confidence interval. This result from the cohort studies seems 
adequately powered, with the total number of patients studied and observed events equal 
to 14,742 and 1684 respectively.       
There was a clear association of MTX with cardiovascular mortality with a 55% lower 
risk in patients with RA and inflammatory polyarthritis. This was very low GRADE 
evidence due to inconsistency (I
2
 = 33%) and publication bias, suggesting that the true 
effect is likely considerably different from the observed effect. 
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MTX was associated with a lower risk of coronary events in patients with RA, psoriasis 
and psoriatic arthritis. A statistically significant 22% lower risk was observed for 
coronary endpoints in patients receiving MTX. However, the evidence was labelled as 
very low GRADE evidence because of the inconsistency in effect across studies (I
2
 = 
33%). 
There was no clear effect of MTX on stroke despite the overall large sample size of 
18,182. Similarly there was not clear association for heart failure. For stroke, this may be 
due to the diverse etiology of cerebrovascular disease, with atherosclerosis accounting for 
only 20% of cases. Heart failure is also diverse and may be due to different causes (e.g. 
viral, idiopathic, valvular), some of which may not be amenable to MTX exposure. 
Due to the low prevalence of ANCA-associated vasculitis, studies assessing MTX and 
cardiovascular disease are lacking. Additionally, cardiac involvement may be different in 
vasculitis than in common rheumatic conditions.
121
 
2. Exploratory findings 
The included studies reported varied types of MTX exposure. It is difficult to identify 
exposure status with certainty in real-world practice, particularly given such issues as 
non-compliance and temporary treatment discontinuation due to remission or side effects. 
Several included studies compared the cardioprotective effect of MTX in initiators versus 
non-initiators and ever-users versus never-users. To assess the association as per 
“intention-to-treat” analysis, we limited our subgroup analysis to initiators versus non-
initiators and reported a 44% lower risk of cardiovascular events. However, this pooled 
analysis is not free from heterogeneity (I
2
 = 68%). We also assessed the effect of MTX in 
studies adjusted for other non-MTX disease-modifying anti-rheumatic drugs and found a 
55% lower risk of cardiovascular events in association with MTX exposure. But again, 
substantial heterogeneity (I
2
 = 66%) should be considered before interpreting this result.  
We found a consistent effect of MTX across different strata. The effect was constant in 
patients from American and European countries where different health care systems exist. 
The effect was also consistent across mean age, suggesting its applicability to different 
patients regardless of age. However, the results from this meta-regression produce an 
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ecological fallacy. A decrease in the risk of cardiovascular events with one unit increase 
in mean age is an association observed between two group-level variables, which may not 
resembles the individual level association. These results would not be as robust as that of 
regression analysis using individual patient data. Finally, the results were consistent 
across publication and accrual years. 
3. Dose-response 
Both low and high cumulative dose MTX treatments are associated with significant 
reductions in cardiovascular events. However, low cumulative dose MTX treatment 
showed more than three times the cardioprotective effect of high cumulative dose MTX 
treatment (39% versus 12% reduction). The difference in effect between the two groups 
was statistically significant (p = 0.001).   
The difference in the cardioprotective effect of low and high dose MTX might be 
explained by differences in their mechanism of action, safety profile, tolerability and 
treatment durability. High-dose MTX is commonly used in cancer treatment, while low-
dose is recommended for the treatment of systemic inflammatory rheumatic diseases.
77,122
 
High-dose MTX acts on rapidly growing cells through anti-proliferative and cytotoxic 
mechanisms. It inhibits dihydrofolate reductase enzyme and stops de novo synthesis of 
DNA, RNA, thymidylates and proteins.
122,123
 As discussed in Chapter 1, low-dose MTX 
mainly exerts an anti-inflammatory effect.
123
 Increased systemic inflammation is known 
to accelerate atherosclerosis; therefore, the anti-inflammatory mechanism of low-dose 
MTX may play a crucial role in preventing cardiovascular disease. An alternate 
explanation is that patients requiring high-dose MTX were sicker than patients requiring 
low-dose MTX, and therefore there may be confounding by disease severity.  
4. Strengths 
In this systematic review, we searched for studies with populations having those 
autoimmune diseases for which MTX is used as either first, second or third line therapy; 
Micha et al included patients with only RA and psoriasis.
72
 In addition to RA and 
psoriasis, we identified studies assessing MTX in systemic sclerosis, myositis and 
inflammatory polyarthritis.    
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We executed a systematic literature search of more than 13,000 citations using a 
comprehensive search strategy; we identified studies from major databases such as Ovid 
Medline, EMBASE, Cochrane library and Web of Science, as well as different grey 
literature sources. Using detailed pre-specified inclusion and exclusion criteria, we 
adjudicated studies independently and in duplicate to increase the validity of the results.  
We identified observational studies for the primary outcome, representing patients treated 
in real world clinical settings. In addition to cardiovascular events, we assessed the 
association of MTX with cardiovascular mortality and all-cause mortality, as well as 
coronary events, stroke and heart failure. To assess an independent and less confounded 
effect of MTX, we only included studies that reported adjusted risk estimates. MTX can 
cause severe adverse events such as hepatotoxicity, pulmonary toxicity, severe infection, 
lymphoproliferative disorders and nephrotoxicity which, consequently, could lead to 
death.
124
 To properly weigh the risks and benefits of MTX on mortality, we included 
randomized controlled trials that reported mortality as an adverse event.  
Despite the minimal heterogeneity of the overall pooled estimate (11%), we checked for 
consistency across study design, study region, type of autoimmune disease, and presence 
of adjustment for cardiovascular risk factors.  
We used the established GRADE system to rate the overall quality of evidence for the 
association of MTX with the reported outcomes. Previous meta-analyses have not rated 
overall quality for their reported outcomes.
72,73
   
5. Limitations 
We found only observational studies for the primary outcome. These studies are not free 
from confounding by selection bias and indication bias. As we discussed earlier in 
chapter-1, these may either underestimate or overestimate the association. Thus, the 
results should be interpreted with caution. We included only adjusted risk estimates in the 
meta-analysis to reduce the impact of confounding. However, residual confounding by 
unmeasured confounders could give rise to biased effect estimates.  
The majority of studies did not adjust for the severity of the underlying disease, which 
could cause a protective association of MTX to be underestimated. Conversely, by 
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decreasing folate levels, MTX can cause hyperhomocysteinemia, a known risk factor for 
cardiovascular disease.
125,126
 Most of the included studies did not adjust for concomitant 
folic acid therapy in their analyses. As well, we identified only four studies reporting 
associations of MTX for high and low doses.  
Some studies used insurance claim data to assess MTX exposure.
63,75,118
 Therefore, 
detailed information regarding treatment duration, doses and compliance were not 
available. Further, none of the studies assessing the primary outcome included MTX as 
time-varying covariate in their analysis. Thus, authors assumed that patients had 
complied with prescribed treatment.  This may present dilution bias in the results; real 
effects may be considerably stronger.  
We were unable to carry out meta-regression for disease duration, an important covariate 
predicting cardiovascular risk in rheumatic diseases;
127
 only three studies reported disease 
duration for the primary outcome. Different studies adjusted for different covariates in 
their statistical models. However, all studies showed a similar direction of effect with 
minimal statistical heterogeneity. Most of the studies failed to report the route of 
administration for MTX treatment. Thus, our results cannot distinguish between oral and 
subcutaneous administration.  
Only one reviewer screened the articles for titles, abstracts and keywords, thus some 
subjectivity and the risk of incorrectly discarding relevant reports cannot be neglected.
128
 
A further limitation is that this review was restricted to English language studies. 
Excluding non-English publications may introduce bias and reduce the precision of 
estimates of treatment effects. It has been shown that trials with positive results are more 
likely to be published in English.
129
 However, Morrison et al found no evidence of bias 
from the use of language restrictions in systematic reviews.
130
  
6. Implications for practice 
MTX in autoimmune diseases (RA, psoriasis, psoriatic arthritis and myositis) is 
associated with a reduced incidence of cardiovascular events. Low-dose MTX offers 
more protective effect than high-dose MTX and is known to cause less toxicity.
123
 
Treatment with MTX may improve physical activity in patients with rheumatic 
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autoimmune disease, and subsequently reduce the risk of diabetes, hypertension and 
obesity. Associations with all-cause mortality and cardiovascular mortality were clear, 
but evidence was graded as very low quality. MTX was not clearly protective in 
associations with stroke and heart failure. Results of this meta-analysis cannot be 
generalized to all MTX treated autoimmune diseases, because of lack of potential 
evidence for ulcerative colitis, Crohn’s disease, systemic lupus erythematosus, transverse 
myelitis, multiple sclerosis, myasthenia gravis, vasculitis and other autoimmune diseases.   
7. Implications for research 
As noted, MTX may be associated with several adverse effects. Assessment of the true 
extent of MTX therapy on cardiovascular outcomes is needed. Currently, the 
Cardiovascular Inflammation Reduction Trial (CIRT) is investigating the anti-
inflammatory effect of low-dose MTX in patients with prior myocardial infarction.
61,62
 
CIRT is testing MTX in patients with high cardiovascular risk, representing a small 
subpopulation of cardiovascular patients who do not have autoimmune disease. 
Regardless of this caveat, results from this well-powered trial could address the efficacy 
and safety of low-dose MTX as noted in our meta-analysis.  
We found numerically protective but statistically non-significant effects of MTX on heart 
failure and stroke. Further high quality research is needed to assess any protective effect 
of MTX on heart failure and stroke.  
Other autoimmune diseases such as systemic lupus erythematosus, inflammatory bowel 
disease, bullous pemphigoid, ANCA associated vasculitis and Takayasu’s arteritis carry 
high risks of cardiovascular events and death.
31,33,41,42,43,44,50
 As we noted, MTX is a 
treatment option for these diseases. At present, almost no evidence exists on the 
association of MTX with cardiovascular disease and mortality for these autoimmune 
diseases. Further research is needed to define the association of MTX with cardiovascular 
disease and mortality in these diseases. Such research, in juxtaposition with our meta-
analysis, would broaden the MTX knowledge base across a wide range of diseases. 
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8. Conclusion 
In conclusion, early intervention with low-dose MTX together with careful monitoring in 
patients with autoimmune disease such as RA, psoriasis, psoriatic arthritis or myositis is 
recommended. This may not only control the underlying disease but hopefully also 
reduce the risk of cardiovascular disease by 25% (if the association we have detected is 
causal). MTX can cause adverse effects, and in such cases, benefits need to be weighed 
against risks.  
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Appendices 
 
Appendix A. Preferred Reporting Item for Systematic Reviews and Meta-analysis (PRISMA) guidelines 
Section/Topic Item 
No. 
Checklist item Page 
number 
Title 1 Identify the report as a systematic review, meta-analysis, or both.  ii 
Structured 
summary 
2 
Provide a structured summary including, as applicable: background; objectives; data sources; 
study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; 
results; limitations; conclusions and implications of key findings; systematic review registration 
number.  
ii 
Rationale 3 Describe the rationale for the review in the context of what is already known.  13 
Objectives 4 
Provide an explicit statement of questions being addressed with reference to participants, 
interventions, comparisons, outcomes, and study design (PICOS).  
13 
Protocol and 
registration 
5 
Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if 
available, provide registration information including registration number.  
16 
Eligibility 
criteria 
6 
Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., 
years considered, language, publication status) used as criteria for eligibility, giving rationale.  
16 
Information 
sources 
7 
Describe all information sources (e.g., databases with dates of coverage, contact with study 
authors to identify additional studies) in the search and date last searched.  
18 
Search 8 
Present full electronic search strategy for at least one database, including any limits used, such 
that it could be repeated.  
18, 72 
Study selection 9 
State the process for selecting studies (i.e., screening, eligibility, included in systematic review, 
and, if applicable, included in the meta-analysis).  
18 
Data collection 
process 
10 
Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) 
and any processes for obtaining and confirming data from investigators.  
20 
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Section/Topic 
Item 
No. 
Checklist item Page 
number 
Data items 11 
List and define all variables for which data were sought (e.g., PICOS, funding sources) and any 
assumptions and simplifications made.  
-- 
Risk of bias in 
individual 
studies 
12 
Describe methods used for assessing risk of bias of individual studies (including specification of 
whether this was done at the study or outcome level), and how this information is to be used in 
any data synthesis.  
20 
Summary 
measures 
13 
State the principal summary measures (e.g., risk ratio, difference in means).  
21 
Synthesis of 
results 
14 
Describe the methods of handling data and combining results of studies, if done, including 
measures of consistency (e.g., I
2
) for each meta-analysis.  
22 
Risk of bias 
across studies 
15 
Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication 
bias, selective reporting within studies).  
23 
Additional 
analyses 
16 
Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), 
if done, indicating which were pre-specified.  
23 
Study selection 17 
Give numbers of studies screened, assessed for eligibility, and included in the review, with 
reasons for exclusions at each stage, ideally with a flow diagram.  
36 
Study 
characteristics 
18 
For each study, present characteristics for which data were extracted (e.g., study size, PICOS, 
follow-up period) and provide the citations.  
29 
Risk of bias 
within studies 
19 
Present data on risk of bias of each study and, if available, any outcome level assessment (see 
item 12).  
34 
Results of 
individual 
studies 
20 
For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data 
for each intervention group (b) effect estimates and confidence intervals, ideally with a forest 
plot.  
41 
Synthesis of 
results 
21 
Present results of each meta-analysis done, including confidence intervals and measures of 
consistency.  
32 
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Section/Topic 
Item 
No. 
Checklist item Page 
number 
Risk of bias 
across studies 
22 Present results of any assessment of risk of bias across studies (see Item 15). 42 
Additional 
analysis 
23 
Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-
regression [see Item 16]).  
42 
Summary of 
evidence 
24 
Summarize the main findings including the strength of evidence for each main outcome; consider 
their relevance to key groups (e.g., healthcare providers, users, and policy makers).  
49 
Limitations 25 
Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., 
incomplete retrieval of identified research, reporting bias).  
54 
Conclusions 26 
Provide a general interpretation of the results in the context of other evidence, and implications 
for future research.  
56 
Funding 27 
Describe sources of funding for the systematic review and other support (e.g., supply of data); 
role of funders for the systematic review.  
-- 
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Appendix B. Search strategy 
Ovid MEDLINE (1946 to Present) 
 
1. Autoimmune Diseases/ 
2. Rheumatic Diseases/  
3. Arthritis, Rheumatoid/  
4. exp Psoriasis/  
5. exp Polymyositis/  
6. Myositis/  
7. exp Lupus Erythematosus, Systemic/ 
8. exp Multiple Sclerosis/  
9. Sjogren's Syndrome/  
10. Pemphigoid, Bullous/  
11. exp Inflammatory Bowel Diseases/  
12. Myelitis, Transverse/  
13. exp Scleroderma, Systemic/  
14. Myasthenia Gravis/   
15. exp Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/ 
16. Polyarteritis Nodosa/  
17. Takayasu Arteritis/  
18. (autoimmune adj (disease* or disorder*)).tw.  
19. (rheumatic adj (disease* or disorder*)).tw.  
20. rheumatoid arthritis.tw.  
21. psoriasis.tw.  
22. psoriatic arthritis.tw. 
23. polymyositis.tw.  
24. dermatomyositis.tw. 
25. (inflammatory adj2 myopath*).tw. 
26. systemic lupus erythematosus.tw.  
27. (SLE and lupus).tw.  
28. multiple sclerosis.tw.  
29. sjogren*.tw.  
30. (bullous adj2 pemphigoid).tw.  
31. inflammatory bowel disease*.tw.  
32. (IBD and (inflammatory and bowel)).tw.  
33. Crohn*.tw.  
34. ulcerative colitis.tw.  
35. transverse myelitis.tw. 
36. systemic sclerosis.tw.  
37. systemic scleroderma.tw.  
38. myasthenia gravis.tw.  
39. wegener* granulomatosis.tw.  
73 
 
 
 
40. microscopic polyangiitis.tw.  
41. microscopic polyarteritis.tw.  
42. (granulomatosis adj2 polyangiitis).tw.  
43. allergic granulomatosis.tw.  
44. eGPA.tw.  
45. eosinophilic granulomatosis.tw.  
46. churg strauss syndrome*.tw.  
47. takayasu arteritis.tw.  
48. (ANCA adj2 vasculitis).tw.  
49. anti neutrophil cytoplasmic antibody associated vasculitis.tw. 
50. or/1-49  
51. Methotrexate/  
52. methotrexate*.tw.  
53. MTX.tw.  
54. (abitrexate or amethopterine or ametopterine or antifolan or artrait or atrexel or 
bendatrexat or biotrexate or carditrex or canceren or dermotrex or ebetrex or emtexate 
or emthexat or emthexate or emtrexate or enthexate or farmitrexat or farmitrexate or 
farmotrex or folex or ifamet or imeth or lantarel or ledertrexate or maxtrex or metex 
or methoblastin or methohexate or methotrate or methotrexat or methotrexato or 
methoxtrexate or methrotrexate or meticil or metoject or metothrexate or metotrexat 
or metotrexate or metotrexin or metrex or mexate or mpi 5004 or mpi5004 or 
neotrexate or novatrex or nsc 740 or nsc740 or otrexup or reumatrex or rheumatrex or 
texate or texorate or trexall or trexan or xaken or zexate).tw.  
55. amethopterin.tw.  
56. or/51-55  
57. Mortality/ 
58. Cause of Death/  
59. Fatal Outcome/  
60. Hospital Mortality/  
61. Mortality, Premature/  
62. Death/  
63. Death, Sudden/ 
64. Death, Sudden, Cardiac/  
65. Life Expectancy/  
66. Life Tables/  
67. Vital Statistics/  
68. mortality.fs.  
69. mortalit*.tw.  
70. (death or dead or die or died or dies).tw.  
71. ((hazard* or cox) adj2 (model* or regression*)).tw. 
72. (sudden adj2 death).tw.  
73. kaplan meier*.tw. 
74. (life table* or lifetable*).tw.  
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75. or/57-74  
76. exp Cardiovascular diseases/  
77. exp Cerebrovascular Disorders/  
78. (cardiac adj2 (event* or arrest* or failure)).tw.  
79. (cardiovascular adj2 (disease* or event* or disorder*)).tw.  
80. (cerebrovascular adj2 (disease* or event* or disorder* or accident*)).tw.  
81. (myocardi* adj2 (infarct* or revascular* or isch?emi*)).tw.  
82. (morbid* adj2 (heart* or coronar* or ischaem* or ischem* or myocard*)).tw.  
83. (heart adj (infarct* or arrest* or attack* or failure or event* or bypass*)).tw.  
84. (coronary adj (disease* or event* or bypas* or graft*)).tw.  
85. (Coronary adj (heart or artery) adj disease*).tw.  
86. stroke*1.tw.  
87. (acute coronary adj2 syndrome*).tw.  
88. apoplexy.tw.  
89. isch?emic heart disease*.tw.  
90. or/76-89  
91. 75 or 90  
92. 50 and 56 
93. 91 and 92  
94. exp animals/ not humans.sh.  
95. 93 not 94  
96. (adolescent or children).tw. or child, preschool.sh.  
97. 95 not 96  
 
EMBASE (1947 to present) 
 
1. autoimmune disease/  
2. rheumatic disease/  
3. rheumatoid arthritis/  
4. psoriasis/  
5. psoriatic arthritis/  
6. polymyositis/  
7. myositis/  
8. polymyositis/  
9. dermatomyositis/  
10. systemic lupus erythematosus/  
11. lupus erythematosus nephritis/  
12. brain vasculitis/  
13. multiple sclerosis/  
14. Sjoegren syndrome/  
15. bullous pemphigoid/  
16. inflammatory bowel disease/  
17. ulcerative colitis/  
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18. Crohn disease/  
19. myelitis/  
20. exp systemic sclerosis/  
21. myasthenia gravis/  
22. ANCA associated vasculitis/  
23. Churg Strauss syndrome/  
24. microscopic polyangiitis/  
25. Wegener granulomatosis/  
26. polyarteritis nodosa/  
27. aorta arch syndrome/  
28. (autoimmune adj (disease* or disorder*)).tw.  
29. (rheumatic adj (disease* or disorder*)).tw.  
30. rheumatoid arthritis.tw.  
31. psoriasis.tw.  
32. psoriatic arthritis.tw.  
33. polymyositis.tw.  
34. dermatomyositis.tw.  
35. (inflammatory adj2 myopath*).tw.  
36. systemic lupus erythematosus.tw.  
37. (SLE and lupus).tw.  
38. multiple sclerosis.tw.  
39. sjogren*.tw.  
40. (bullous adj2 pemphigoid).tw.  
41. inflammatory bowel disease*.tw.  
42. (IBD and (inflammatory and bowel)).tw.  
43. Crohn*.tw.  
44. ulcerative colitis.tw.  
45. transverse myelitis.tw.  
46. systemic sclerosis.tw.  
47. systemic scleroderma.tw.  
48. myasthenia gravis.tw.  
49. wegener* granulomatosis.tw.  
50. microscopic polyangiitis.tw.  
51. microscopic polyarteritis.tw.  
52. (granulomatosis adj2 polyangiitis).tw.  
53. allergic granulomatosis.tw.  
54. eGPA.tw.  
55. eosinophilic granulomatosis.tw.  
56. churg strauss syndrome*.tw.  
57. takayasu arteritis.tw.  
58. (ANCA adj2 vasculitis).tw.  
59. antineutrophil cytoplasmic antibody associated vasculitis.tw.  
60. or/1-59  
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61. methotrexate/  
62. methotrexate.tw.  
63. MTX.tw.  
64. (abitrexate or amethopterine or ametopterine or antifolan or artrait or atrexel or 
bendatrexat or biotrexate or carditrex or canceren or dermotrex or ebetrex or emtexate 
or emthexat or emthexate or emtrexate or enthexate or farmitrexat or farmitrexate or 
farmotrex or folex or ifamet or imeth or lantarel or ledertrexate or maxtrex or metex 
or methoblastin or methohexate or methotrate or methotrexat or methotrexato or 
methoxtrexate or methrotrexate or meticil or metoject or metothrexate or metotrexat 
or metotrexate or metotrexin or metrex or mexate or mpi 5004 or mpi5004 or 
neotrexate or novatrex or nsc 740 or nsc740 or otrexup or reumatrex or rheumatrex or 
texate or texorate or trexall or trexan or xaken or zexate).tw.  
65. amethopterin.tw.  
66. or/61-65  
67. mortality/  
68. "cause of death"/  
69. fatality/  
70. premature mortality/  
71. death/  
72. exp sudden death/  
73. life expectancy/  
74. life table/  
75. Vital Statistics/  
76. vital statistics/  
77. mortalit*.tw.  
78. (death or dead or die or died or dies).tw.  
79. ((hazard* or cox) adj2 (model* or regression*)).tw.  
80. (sudden adj2 death).tw.  
81. kaplan meier*.tw.  
82. (life table* or lifetable*).tw.  
83. or/67-82  
84. exp cardiovascular disease/  
85. exp cerebrovascular disease/  
86. cardiovascular mortality/  
87. (cardiac adj2 (event* or arrest* or failure)).tw.  
88. (cardiovascular adj2 (disease* or event* or disorder*)).tw.  
89. (cerebrovascular adj2 (disease* or event* or disorder* or accident*)).tw.  
90. (myocardi* adj2 (infarct* or revascular* or isch?emi*)).tw.  
91. (morbid* adj2 (heart* or coronar* or isch?em* or myocard*)).tw.  
92. (heart adj (infarct* or arrest* or attack* or failure or event* or bypass*)).tw.  
93. (coronary adj (disease* or event* or bypas* or graft*)).tw.  
94. (coronary adj (heart or artery) adj disease*).tw.  
95. stroke*1.tw.  
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96. (acute coronary adj2 syndrome*).tw. 
97. apoplexy.tw.  
98. isch?emic heart disease*.tw.  
99. or/84-98  
100. 83 or 99  
101. 60 and 66  
102. 100 and 101  
103. (animal$ not human$).sh,hw.  
104. 102 not 103  
105. exp pediatrics/  
106. child/  
107. adolescent/  
108. (adolescent* or child* or preschool* or pre school*).tw.  
109. or/105-108  
110. 104 not 109  
 
Web of Science 
 
1. TS=(((autoimmune OR rheumatic) NEAR/1 disease*) OR rheumatoid arthritis OR 
psoriasis OR polymyositis OR myositis OR "systemic lupus erythematosus" OR 
"multiple sclerosis" OR sjogren* OR "bullous pemphigoid" OR dermatomyositis OR 
(inflammatory NEAR/1 myopath*) OR ("inflammatory bowel" NEAR/1 disease*) or 
crohn* or "ulcerative colitis")  
DocType=All document types; Language=All languages; 
2. TS=(methotrexate OR MTX OR abitrexate OR amethopterine OR ametopterine OR 
antifolan OR artrait OR atrexel OR bendatrexat OR biotrexate OR carditrex OR 
canceren OR dermotrex OR ebetrex OR emtexate OR emthexat OR emthexate OR 
emtrexate OR enthexate OR farmitrexat OR farmitrexate OR farmotrex OR folex OR 
ifamet OR imeth OR lantarel OR ledertrexate OR maxtrex OR metex OR 
methoblastin OR methohexate OR methotrate OR methotrexat OR methotrexato OR 
methoxtrexate OR methrotrexate OR meticil OR metoject OR metothrexate OR 
metotrexat OR metotrexate OR metotrexin OR metrex OR mexate OR mpi 5004 OR 
mpi5004 OR neotrexate OR novatrex OR nsc 740 OR nsc740 OR otrexup OR 
reumatrex OR rheumatrex OR texate OR texorate OR trexall OR trexan OR xaken 
OR zexate OR amethopterin)  
DocType=All document types; Language=All languages; 
3. (#2 AND #1)  
DocType=All document types; Language=All languages; 
4. TS=(mortalit* OR fatal* OR death OR dead OR die OR died OR dies OR "life table" 
OR "life tables" OR lifetable* OR "hazard model" OR "kaplan meier" OR "cox 
model")  
DocType=All document types; Language=All languages; 
5. TS=((cardiac NEAR/2 (event* OR arrest* OR failure)) OR ((cardiovascular OR 
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cerebrovascular) NEAR/2 (disease* OR event* OR disorder* OR accident*)) OR 
(myocardi* NEAR/2 (infarct* OR revascular* OR isch?em*)) OR (morbid* NEAR/2 
(heart* OR coronar* OR isch?em* OR myocard*)) OR (heart NEAR/1 (infarct* OR 
arrest* OR attack* OR failure OR event*)) OR (coronary NEAR/1 (disease* OR 
event OR bypas* OR graft*)) OR coronary heart disease* OR coronary artery 
disease* OR stroke OR strokes)  
DocType=All document types; Language=All languages; 
6. (#5 OR #4)  
DocType=All document types; Language=All languages; 
7. (#3 AND #6)  
DocType=All document types; Language=All languages; 
 
The Cochrane Library 
 
1. MeSH descriptor: [Autoimmune Diseases] this term only 
2. MeSH descriptor: [Rheumatic Diseases] this term only 
3. MeSH descriptor: [Arthritis, Rheumatoid] this term only 
4. MeSH descriptor: [Psoriasis] explode all trees 
5. MeSH descriptor: [Myositis] this term only 
6. MeSH descriptor: [Polymyositis] this term only 
7. MeSH descriptor: [Dermatomyositis] this term only 
8. MeSH descriptor: [Lupus Erythematosus, Systemic] 1 tree(s) exploded 
9. MeSH descriptor: [Multiple Sclerosis] 1 tree(s) exploded 
10. MeSH descriptor: [Sjogren's Syndrome] this term only 
11. MeSH descriptor: [Pemphigoid, Bullous] this term only 
12. MeSH descriptor: [Inflammatory Bowel Diseases] explode all trees 
13. MeSH descriptor: [Myelitis, Transverse] 3 tree(s) exploded 
14. MeSH descriptor: [Myasthenia Gravis] this term only 
15. MeSH descriptor: [Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis] 1 
tree(s) exploded 
16. MeSH descriptor: [Polyarteritis Nodosa] this term only 
17. MeSH descriptor: [Takayasu Arteritis] this term only 
18. MeSH descriptor: [Scleroderma, Systemic] explode all trees 
19. (AUTOIMMUNE near/2 (DISEASE* or DISORDER*)):ti,ab,kw  
20. (RHEUMATIC near/2 (DISEASE* or DISORDER*)):ti,ab,kw  
21. (RHEUMATOID next ARTHRITIS) 
22. (PSORIASIS) 
23. (PSORIATIC next ARTHRITIS)  
24. (POLYMYOSITIS or DERMATOMYOSITIS)  
25. (INFLAMMATORY near/2 MYOPATH*)  
26. (SYSTEMIC next LUPUS next ERYTHEMATOSUS)  
27. (SLE and LUPUS)  
28. (MULTIPLE next SCLEROSIS)  
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29. (SJOGREN*)  
30. (BULLOUS near/2 PEMPHIGOID)  
31. (INFLAMMATORY next BOWEL next DISEASE*)  
32. (IBD and (INFLAMMATORY and BOWEL))  
33. (CROHN*)  
34. (ULCERATIVE next COLITIS)  
35. (TRANSVERSE next MYELITIS)  
36. (SYSTEMIC near/2 SCLEROSIS)  
37. (SYSTEMIC near/2 SCLERODERMA)  
38. (MYASTHENIA next GRAVIS)  
39. (WEGENER* next GRANULOMATOSIS)  
40. (MICROSCOPIC next POLYANGIITIS)  
41. (MICROSCOPIC next POLYARTERITIS)  
42. (GRANULOMATOSIS near/2 POLYANGIITIS)  
43. (ALLERGIC next GRANULOMATOSIS)  
44. (EGPA)  
45. (EOSINOPHILIC next GRANULOMATOSIS)  
46. (CHURG next STRAUSS next SYNDROME)  
47. (ANCA near/2 VASCULITIS)  
48. (#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 
or #15 or #16 or #17 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 
or #28 or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37 or #38 or #39 
or #40 or #41 or #42 or #43 or #44 or #45 or #46 or #47) 
49. MeSH descriptor: [Methotrexate] this term only 
50. MeSH descriptor: [Aminopterin] this term only 
51. (METHOTREXATE)  
52. (AMINOPTERIN)  
53. (MTX)  
54. (ABITREXATE or AMETHOPTERIN or AMETHOPTERINE or AMETOPTERINE 
or ANTIFOLAN or ARTRAIT or ATREXEL or BENDATREXAT or 
BIOTREXATE or CARDITREX or CANCEREN or DERMOTREX or EBETREX 
or EMTEXATE or EMTHEXAT or EMTHEXATE or EMTREXATE or 
ENTHEXATE or FARMITREXAT or FARMITREXATE or FARMOTREX or 
FOLEX or IFAMET or IMETH or LANTAREL or LEDERTREXATE or 
MAXTREX or METEX or METHOBLASTIN or METHOHEXATE or 
METHOTRATE or METHOTREXAT or METHOTREXATO or 
METHOXTREXATE or METHROTREXATE or METICIL or METOJECT or 
METOTHREXATE or METOTREXAT or METOTREXATE or METOTREXIN or 
METREX or MEXATE or MPI 5004 or MPI5004 or NEOTREXATE or 
NOVATREX or NSC 740 or NSC740 or OTREXUP or REUMATREX or 
RHEUMATREX or TEXATE or TEXORATE or TREXALL or TREXAN or 
XAKEN or ZEXATE)  
55. (#49 or #50 or #51 or #52 or #53 or #54) 
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56. (#48 and #55) 
57. MeSH descriptor: [Mortality] this term only 
58. MeSH descriptor: [Cause of Death] this term only   
59. MeSH descriptor: [Fatal Outcome] this term only 
60. MeSH descriptor: [Hospital Mortality] this term only 
61. MeSH descriptor: [Mortality, Premature] this term only 
62. MeSH descriptor: [Death] this term only 
63. MeSH descriptor: [Death, Sudden] this term only 
64. MeSH descriptor: [Death, Sudden, Cardiac] this term only 
65. MeSH descriptor: [Death Certificates] this term only 
66. MeSH descriptor: [Life Expectancy] this term only 
67. MeSH descriptor: [Life Tables] this term only 
68. MeSH descriptor: [Vital Statistics] this term only 
69. ((HAZARD* or COX) near/2 MODEL*)  
70. (SUDDEN near/2 DEATH)  
71. (MORTALIT* or DIED or DIE or DEATH or DEAD)  
72. (KAPLAN next MEIER*)  
73. (LIFE next TABLE*) or (LIFETABLE*)  
74. (#57 or #58 or #59 or #60 or #61 or #62 or #63 or #64 or #65 or #66 or #67 or #68 or 
#69 or #70 or #71 or #72 or #73) 
75. MeSH descriptor: [Cardiovascular Diseases] explode all trees 
76. MeSH descriptor: [Cerebrovascular Disorders] explode all trees 
77. (CARDIAC near/2 (EVENT* or ARREST* or FAILURE))  
78. (CARDIOVASCULAR near/2 (DISEASE* or EVENT* or DISORDER*))  
79. (CEREBROVASCULAR near/2 (DISEASE* or EVENT* or DISORDER* or 
ACCIDENT*)) 
80. (HEART near/2 (INFARCT* or ARREST* or DISEASE* or ATTACK* or 
FAILURE or EVENT* or BYPAS*))  
81. (CORONARY near/2 (DISEASE* or EVENT* or BYPAS* or GRAFT*)) 
82. (MYOCARDIAL* near/2 (INFARCT* or RE?VASCULAR* or ISCH?EMI*)) 
83. (MORBID* near (HEART* or CORONARY* or ISCH?EMI* or MYOCARD*))  
84. (CORONARY next (DISEASE* or EVENT* or BYPAS* or GRAFT*)) 
85. (STROKE or STROKES)  
86. (ISCH?EMIC next HEART next DISEASE*)  
87. (APOPLEXY) 
88. (#75 or #76 or #77 or #78 or #79 or #80 or #81 or #82 or #83 or #84 or #85 or #86 or 
#87) 
89. (#74 or #88) 
90. (#56 and #89) 
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Google scholar 
 
Methotrexate AND “rheumatoid arthritis” AND (coronary OR cardiovascular OR 
myocardial OR ischemic OR infarction OR infarct OR stroke OR cerebrovascular OR 
ischemia OR vascular OR angina OR mortality OR morbidity OR death OR dead OR chd 
OR cad OR ihd) 
 
Methotrexate AND “Psoriasis” AND (coronary OR cardiovascular OR myocardial OR 
ischemic OR infarction OR infarct OR stroke OR cerebrovascular OR ischemia OR 
vascular OR angina OR mortality OR morbidity OR death OR dead OR chd OR cad OR 
ihd) 
 
Methotrexate AND “Psoriatic arthritis” AND (coronary OR cardiovascular OR 
myocardial OR ischemic OR infarction OR infarct OR stroke OR cerebrovascular OR 
ischemia OR vascular OR angina OR mortality OR morbidity OR death OR dead OR chd 
OR cad OR ihd) 
 
Methotrexate AND “dermatomyositis” AND (coronary OR cardiovascular OR 
myocardial OR ischemic OR infarction OR infarct OR stroke OR cerebrovascular OR 
ischemia OR vascular OR angina OR mortality OR morbidity OR death OR dead OR chd 
OR cad OR ihd) 
 
Methotrexate AND “polymyositis” AND (coronary OR cardiovascular OR myocardial 
OR ischemic OR infarction OR infarct OR stroke OR cerebrovascular OR ischemia OR 
vascular OR angina OR mortality OR morbidity OR death OR dead OR chd OR cad OR 
ihd) 
 
Methotrexate AND “systemic lupus erythematosus” AND (coronary OR cardiovascular 
OR myocardial OR ischemic OR infarction OR infarct OR stroke OR cerebrovascular 
OR ischemia OR vascular OR angina OR mortality OR morbidity OR death OR dead OR 
chd OR cad OR ihd) 
 
Methotrexate AND “multiple sclerosis” AND (coronary OR cardiovascular OR 
myocardial OR ischemic OR infarction OR infarct OR stroke OR cerebrovascular OR 
ischemia OR vascular OR angina OR mortality OR morbidity OR death OR dead OR chd 
OR cad OR ihd) 
 
Methotrexate AND “Sjogren’s syndrome” AND (coronary OR cardiovascular OR 
myocardial OR ischemic OR infarction OR infarct OR stroke OR cerebrovascular OR 
ischemia OR vascular OR angina OR mortality OR morbidity OR death OR dead OR chd 
OR cad OR ihd) 
 
Methotrexate AND “bullous pemphigoid” AND (coronary OR cardiovascular OR 
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myocardial OR ischemic OR infarction OR infarct OR stroke OR cerebrovascular OR 
ischemia OR vascular OR angina OR mortality OR morbidity OR death OR dead OR chd 
OR cad OR ihd) 
 
Methotrexate AND “crohn’s disease” AND (coronary OR cardiovascular OR myocardial 
OR ischemic OR infarction OR infarct OR stroke OR cerebrovascular OR ischemia OR 
vascular OR angina OR mortality OR morbidity OR death OR dead OR chd OR cad OR 
ihd) 
 
Methotrexate AND “ulcerative colitis” AND (coronary OR cardiovascular OR 
myocardial OR ischemic OR infarction OR infarct OR stroke OR cerebrovascular OR 
ischemia OR vascular OR angina OR mortality OR morbidity OR death OR dead OR chd 
OR cad OR ihd) 
 
Methotrexate AND “transverse myelitis” AND (coronary OR cardiovascular OR 
myocardial OR ischemic OR infarction OR infarct OR stroke OR cerebrovascular OR 
ischemia OR vascular OR angina OR mortality OR morbidity OR death OR dead OR chd 
OR cad OR ihd) 
 
Methotrexate AND “systemic sclerosis” AND (coronary OR cardiovascular OR 
myocardial OR ischemic OR infarction OR infarct OR stroke OR cerebrovascular OR 
ischemia OR vascular OR angina OR mortality OR morbidity OR death OR dead OR chd 
OR cad OR ihd) 
Methotrexate AND “myasthenia gravis” AND (coronary OR cardiovascular OR 
myocardial OR ischemic OR infarction OR infarct OR stroke OR cerebrovascular OR 
ischemia OR vascular OR angina OR mortality OR morbidity OR death OR dead OR chd 
OR cad OR ihd) 
 
Methotrexate AND “Wegener’s granulomatosis” AND (coronary OR cardiovascular OR 
myocardial OR ischemic OR infarction OR infarct OR stroke OR cerebrovascular OR 
ischemia OR vascular OR angina OR mortality OR morbidity OR death OR dead OR chd 
OR cad OR ihd) 
 
Methotrexate AND “microscopic polyangitis” AND (coronary OR cardiovascular OR 
myocardial OR ischemic OR infarction OR infarct OR stroke OR cerebrovascular OR 
ischemia OR vascular OR angina OR mortality OR morbidity OR death OR dead OR chd 
OR cad OR ihd) 
 
Methotrexate AND “eosinophilic granulomatosis with polyangitis” AND (coronary OR 
cardiovascular OR myocardial OR ischemic OR infarction OR infarct OR stroke OR 
cerebrovascular OR ischemia OR vascular OR angina OR mortality OR morbidity OR 
death OR dead OR chd OR cad OR ihd) 
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Methotrexate AND “takayasu’s arteritis” AND (coronary OR cardiovascular OR 
myocardial OR ischemic OR infarction OR infarct OR stroke OR cerebrovascular OR 
ischemia OR vascular OR angina OR mortality OR morbidity OR death OR dead OR chd 
OR cad OR ihd) 
 
Methotrexate AND “ANCA” AND “vasculitis” AND (coronary OR cardiovascular OR 
myocardial OR ischemic OR infarction OR infarct OR stroke OR cerebrovascular OR 
ischemia OR vascular OR angina OR mortality OR morbidity OR death OR dead OR chd 
OR cad OR ihd) 
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Appendix C. Study Eligibility Assessment Form 
Study No.:      RefWorks ID:   
Study title: 
Last name of first author:    Year of publication:  
Reviewer’s Initial: 
 
All criteria must met 
 
1 Is the study published in English language? 
 
Yes        No 
2 Study design (Cohort, Case-control or RCT) 
 
Yes        No 
3 Did the study report any of the following events in its analysis 
including adverse event (AE) analysis? 
1. Cardiovascular events 
2. Fatal/non-fatal MI 
3. ACS/IHD/CAD 
4. Sudden cardiac death 
5. Heart failure 
6. Cardiac arrest 
7. Stroke 
8. Hospitalization due to cardiac event 
9. All-cause mortality 
10. Cardiovascular mortality 
 
Yes        No 
4 Did the study report the association of MTX with any of the 
outcomes listed above in its analysis including AE analysis? 
 
Yes        No 
5 Did the study produce an analysis (including AE analysis) that 
compares the outcome of interest between MTX users versus 
non-users or placebo group? 
 
Yes        No 
6 Did the study report any of the following statistical 
measuresfor the association of MTX with the outcomes of 
interest? 
1. Number of patients experiencing event (n) 
2. Incidence rates 
3. Cumulative incidence 
4. OR (95% CI) 
5. RR (95% CI) 
6. Risk ratio (95% CI) 
 
Yes        No 
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7 Did the study include patients with any of the following 
autoimmune diseases? 
1. Rheumatoid arthritis 
2. Psoriasis 
3. Psoriatic arthritis 
4. Dermatomyositis 
5. Polymyositis 
6. Myositis 
7. Systemic Lupus Erythematosus 
8. Multiple sclerosis 
9. Sjogren’s syndrome 
10. Bullous pemphigoid  
11. Crohn’s disease 
12. Ulcerative colitis 
13. Transverse Myelitis 
14. Systemic sclerosis (Scleroderma) 
15. Myasthenia Gravis 
16. ANCA associated vasculitis 
17. Takayasu’s arteritis 
 
Yes        No 
8 Additional comments ____________________________________ 
 
9 Reviewer's final assessment. 
1. Include 
2. Exclude 
3. Unclear 
 
Include 
Exclude 
Unclear 
 
10 
 
Reason for exclusion/unclear study_________________________ 
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Appendix D. Data Abstraction Form 
1. Citation details 
 
Study No.  
RefWorks ID.  
Data abstraction date  
Abstracter’s initial  
First author  
Second author (if only two authors on the 
study 
 
Publication year  
 
2. Study characteristics 
 
Publication type 
      Full text 
      Abstract 
      Other (Specify) _______________ 
Country of study  
Study design 
      Randomized Controlled Trial (RCT) 
      Case-control 
      Cohort     
Data collection 
      Prospective 
      Retrospective 
Study setting 
      Hospital based 
      Out-patient  
      Unclear 
Accrual start date (dd/mm/yyyy)  
Accrual end date (dd/mm/yyyy)  
Follow start date (dd/mm/yyyy)  
Follow end date (dd/mm/yyyy)  
Total follow up period (months)  
Inclusion criteria  
Exclusion criteria 
 
Source of information for study sample 
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3. Additional information for RCT 
 
Trial design 
      Parallel   
      Cross-over          
      Factorial 
      Other (Specify) _______________ 
Treatment arms  
 
4. Characteristics of underling disease 
 
Disease  
Diagnostic criteria  
Disease duration  
(mean, SD, median IQR, range) 
 
Severity of underlying disease  
 
5. Sample characteristics 
 
Sample size (cohort )  
Sample size (cases or MTX group)  
Sample size (controls or non-MTX group)  
Age (cohort) (mean, SD, median, IQR)  
Age (cases or MTX group) 
(mean, SD, median, IQR) 
 
Age (controls or non-MTX group)  
% Female or Gender (cohort)  
% Female (cases or MTX group)  
% Female (controls or non-MTX group)  
% with baseline CVD (cohort)  
% with baseline CVD (cases or MTX group)  
% with baseline CVD (controls or non-MTX 
group) 
 
Does the sample contain patients with RA? 
      Yes 
      No 
 
6. Exposure characteristics (MTX) 
 
MTX exposure definition  
Dose of MTX reported 
      Yes 
      No 
Dose in mg/week (mean, median, SD)  
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Duration of MTX use  
(months) (mean, median, SD) 
 
Exposure type 
      Initiators vs. non-initiators 
      Ever-users vs. never-users 
      Current-users vs. non-current users 
      Unclear 
Data source of MTX exposure 
 
 
7. Outcome characteristics 
 
Outcome Definition Data source  
1.    
2.    
3.    
Did the study report any of the CVD or 
mortality outcomes as adverse event? 
     Yes 
    No 
     Yes 
    No 
Did the study exclude patients with prior or 
current CVD in analysis? 
 
8. Analysis and results 
 
Total observation time 
(mean-SD, median- range) 
 
Person-years or months exposure of whole 
cohort 
 
 
Outcome of 
interest 
Person-
years 
exposure 
for 
particular 
outcome 
Events in 
cohort 
Events in 
cases or 
MTX 
group 
Events 
in 
control 
group 
Sample 
size 
(cohort) 
(n) 
Sample 
size  
(cases or 
MTX 
group) 
(n2) 
Sample 
size 
(control 
or non-
MTX 
group) 
(n3) 
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Outcome of 
interest 
Effect 
measures 
(RR, OR, 
HR, rate 
ratio, 
IRR) 
Adjusted 
effect 
estimate 
(MTX vs. 
no-MTX) 
95% CI of 
adjusted 
estimate 
(MTX vs. 
no-MTX) 
p-value 
of 
adjusted 
estimate 
(MTX 
vs. no-
MTX) 
Adjusted 
variables 
in the 
analysis 
Methods 
used to 
adjust 
confounding 
Source of 
outcome in 
article 
1. Page # 
2. Table # 
3. Fig.# 
        
        
        
 
 
       
        
 
Did the analysis include MTX as time-
varying covariate? 
      Yes 
      No 
List all other time varying covariates in the 
model 
 
 
9. Subgroup analysis 
 
Subgroups 
Operational 
definition 
Adjusted 
effect 
estimate 
(MTX vs. 
no-MTX) 
95% CI of 
adjusted 
estimate 
(MTX vs. 
no-MTX) 
p-value 
of 
adjusted 
estimate 
(MTX 
vs. no-
MTX) 
Adjusted 
variables 
in the 
analysis 
Formal 
test of 
interaction 
Source of 
outcome 
in article 
1. Page # 
2. Table # 
3. Fig.# 
        
        
        
        
 
10. Dose response analysis 
 
MTX dose group Definition 
Adjusted 
effect 
estimate 
(MTX vs. no-
MTX) 
95% CI of 
adjusted 
estimate 
(MTX vs. no-
MTX) 
p-value of 
adjusted 
estimate 
(MTX vs. 
no-MTX) 
Adjusted 
variables 
in the 
analysis 
Source of 
outcome 
(article) 
1.page #  
2. Table # 
3. Fig.#: 
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11. Additional comment 
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Appendix E. Newcastle-Ottawa Quality Assessment Scale 
 
CASE CONTROL STUDIES 
Note: A study can be awarded a maximum of one star for each numbered item within the 
Selection and Exposure categories. A maximum of two stars can be given for 
Comparability. 
 
Selection 
1) Is the case definition adequate? 
a) Yes, with independent validation * 
b) Yes, e.g. record linkage or based on self-reports 
c) No description 
2) Representativeness of the cases 
a) Consecutive or obviously representative series of cases * 
a) Potential for selection biases or not stated 
3) Selection of Controls 
a) Community controls * 
b) Hospital controls 
c) No description 
4) Definition of Controls 
a) No history of disease (endpoint) * 
b) No description of source 
Comparability 
1) Comparability of cases and controls on the basis of the design or analysis 
a) Study controls for _______________ (Select the most important factor) * 
b) Study controls for any additional factor (This criteria could be modified to 
indicate specific control for a second important factor) 
 
Exposure 
1) Ascertainment of exposure 
a) Secure record (e.g. surgical records) * 
b) Structured interview where blind to case/control status * 
c) Interview not blinded to case/control status 
d) Written self-report or medical record only 
e) No description 
2) Same method of ascertainment for cases and controls 
a) Yes * 
b) No 
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3) Non-Response rate 
a) Same rate for both groups * 
b) Non respondents described 
c) Rate different and no designation 
 
COHORT STUDIES 
Note: A study can be awarded a maximum of one star for each numbered item within the 
Selection and Outcome categories. A maximum of two stars can be given for 
Comparability 
 
Selection 
1) Representativeness of the exposed cohort 
a) Truly representative of the average _______________ (describe) in the 
community *  
b) Somewhat representative of the average ______________ in the community * 
c) Selected group of users e.g. nurses, volunteers 
d) No description of the derivation of the cohort 
2) Selection of the non-exposed cohort 
a) Drawn from the same community as the exposed cohort * 
b) Drawn from a different source 
c) No description of the derivation of the non-exposed cohort  
3) Ascertainment of exposure 
a) Secure record (e.g. surgical records) * 
b) Structured interview * 
c) Written self-report 
d) No description 
4) Demonstration that outcome of interest was not present at start of study 
a) Yes * 
b) No 
Comparability 
1) Comparability of cohorts on the basis of the design or analysis 
a) Study controls for _____________ (select the most important factor) * 
b) Study controls for any additional factor * (This criteria could be modified to 
indicate specific control for a second important factor)  
 
Outcome 
1) Assessment of outcome  
a) Independent blind assessment *  
b) Record linkage * 
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c) Self-report  
d) No description 
 
2) Was follow-up long enough for outcomes to occur 
a) Yes (select an adequate follow up period for outcome of interest) * 
b) No 
3) Adequacy of follow up of cohorts 
a) Complete follow up - all subjects accounted for *  
b) Subjects lost to follow up unlikely to introduce bias - small number lost - > ____ 
% (select an adequate %) follow up, or description provided of those lost) * 
c) Follow up rate < ____% (select an adequate %) and no description of those lost 
d) No statement 
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Appendix F. The Cochrane Collaboration’s tool for assessing risk of bias 
Domain Description Review authors’ judgement 
Sequence generation Describe the method used to generate the allocation sequence in 
sufficient detail to allow an assessment of whether it should produce 
comparable groups. 
Was the allocation sequence 
adequately generated? 
Allocation concealment Describe the method used to conceal the allocation sequence in 
sufficient detail to determine whether intervention allocations could 
have been foreseen in advance of, or during, enrolment. 
Was allocation adequately 
concealed? 
Blinding of participants, personnel 
and outcome assessors Assessments 
should be made for each main 
outcome (or class of outcomes) 
Describe all measures used, if any, to blind study participants and 
personnel from knowledge of which intervention a participant 
received. Provide any information relating to whether the intended 
blinding was effective. 
Was knowledge of the allocated 
intervention adequately prevented 
during the study? 
Incomplete outcome data 
Assessments should be made for each 
main outcome (or class of outcomes) 
Describe the completeness of outcome data for each main outcome, 
including attrition and exclusions from the analysis. State whether 
attrition and exclusions were reported, the numbers in each 
intervention group (compared with total randomized participants), 
reasons for attrition/exclusions where reported, and any re-inclusions 
in analyses performed by the review authors. 
Were incomplete outcome data 
adequately addressed? 
Selective outcome reporting State how the possibility of selective outcome reporting was 
examined by the review authors, and what was found. 
Are reports of the study free of 
suggestion of selective outcome 
reporting? 
Other sources of bias State any important concerns about bias not addressed in the other 
domains in the tool. If particular questions/entries were pre-specified 
in the review’s protocol, responses should be provided for each 
question/entry. 
Was the study apparently free of 
other problems that could put it at 
a high risk of bias? 
 
Possible approach for summary assessments outcome (across domains) within and across studies 
 
Risk of bias Interpretation Within a study Across studies 
Low risk of bias Plausible bias unlikely to Low risk of bias for all key Most information is from studies at low risk 
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seriously alter the results. domains. of bias. 
Unclear risk of bias Plausible bias that raises some 
doubt about the results 
Unclear risk of bias for one or 
more key domains. 
Most information is from studies at low or 
unclear risk of bias. 
High risk of bias Plausible bias that seriously 
weakens confidence in the results. 
High risk of bias for one or more 
key domains. 
The proportion of information from studies at 
high risk of bias is sufficient to affect the 
interpretation of the results. 
 
 
Criteria for judging risk of bias in the ‘Risk of bias’ assessment tool 
SEQUENCE GENERATION 
Was the allocation sequence adequately generated? [Short form: Adequate sequence generation?] 
Criteria for a judgement of ‘YES’ 
(i.e. low risk of bias). 
The investigators describe a random component in the sequence generation process such as: 
 Referring to a random number table; Using a computer random number generator; Coin tossing; Shuffling 
cards or envelopes; Throwing dice; Drawing of lots; Minimization*. 
*Minimization may be implemented without a random element, and this is considered to be equivalent to being 
random. 
Criteria for the judgement of ‘NO’ 
(i.e. high risk of bias). 
The investigators describe a non-random component in the sequence generation process. Usually, the description 
would involve some systematic, non-random approach, for example: 
 Sequence generated by odd or even date of birth; 
 Sequence generated by some rule based on date (or day) of admission; 
 Sequence generated by some rule based on hospital or clinic record number. 
Other non-random approaches happen much less frequently than the systematic approaches mentioned above and 
tend to be obvious. They usually involve judgement or some method of non-random categorization of 
participants, for example: 
 Allocation by judgement of the clinician; 
 Allocation by preference of the participant; 
 Allocation based on the results of a laboratory test or a series of tests; 
 Allocation by availability of the intervention. 
Criteria for the judgment of 
‘UNCLEAR’ (uncertain risk of 
Insufficient information about the sequence generation process to permit judgement of ‘Yes’ or ‘No’. 
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bias). 
ALLOCATION CONCEALMENT 
Was allocation adequately concealed? [Short form: Allocation concealment?] 
Criteria for a judgement of 
‘YES’ (i.e. low risk of bias). 
Participants and investigators enrolling participants could not foresee assignment because one of the following, or an 
equivalent method, was used to conceal allocation: 
 Central allocation (including telephone, web-based, and pharmacy-controlled, randomization); 
 Sequentially numbered drug containers of identical appearance; 
 Sequentially numbered opaque, sealed envelopes. 
Criteria for the judgement of 
‘NO’ (i.e. high risk of bias). 
Participants or investigators enrolling participants could possibly foresee assignments and thus introduce selection 
bias, such as allocation based on: 
 Using an open random allocation schedule (e.g. a list of random numbers); 
 Assignment envelopes were used without appropriate safeguards (e.g. if envelopes were unsealed or non-opaque 
or not sequentially numbered); 
 Alternation or rotation; 
 Date of birth; 
 Case record number; 
 Any other explicitly unconcealed procedure. 
Criteria for the judgement of 
‘UNCLEAR’ (uncertain risk of 
bias). 
Insufficient information to permit judgement of ‘Yes’ or ‘No’. This is usually the case if the method of concealment 
is not described or not described in sufficient detail to allow a definite judgement – for example if the use of 
assignment envelopes is described, but it remains unclear whether envelopes were sequentially numbered, opaque 
and sealed.. 
BLINDING OF PARTICIPANTS, PERSONNEL AND OUTCOME ASSESSORS 
Was knowledge of the allocated interventions adequately prevented during the study? [Short form: Blinding?] 
Criteria for a judgement of 
‘YES’ (i.e. low risk of bias). 
Any one of the following: 
 No blinding, but the review authors judge that the outcome and the outcome measurement are not likely to be 
influenced by lack of blinding; 
 Blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken; 
 Either participants or some key study personnel were not blinded, but outcome assessment was blinded and the 
non-blinding of others unlikely to introduce bias. 
Criteria for the judgement of Any one of the following: 
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‘NO’ (i.e. high risk of bias).  No blinding or incomplete blinding, and the outcome or outcome measurement is likely to be influenced by lack 
of blinding; 
 Blinding of key study participants and personnel attempted, but likely that the blinding could have been broken; 
 Either participants or some key study personnel were not blinded, and the non-blinding of others likely to 
introduce bias. 
Criteria for the judgement of 
‘UNCLEAR’ (uncertain risk of 
bias). 
Any one of the following: 
 Insufficient information to permit judgement of ‘Yes’ or ‘No’; 
 The study did not address this outcome. 
INCOMPLETE OUTCOME DATA 
Were incomplete outcome data adequately addressed? [Short form: Incomplete outcome data addressed?] 
Criteria for a judgement of 
‘YES’ (i.e. low risk of bias). 
Any one of the following: 
 No missing outcome data; 
 Reasons for missing outcome data unlikely to be related to true outcome (for survival data, censoring unlikely to 
be introducing bias); 
 Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data 
across groups; 
 For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk not 
enough to have a clinically relevant impact on the intervention effect estimate; 
 For continuous outcome data, plausible effect size (difference in means or standardized difference in means) 
among missing outcomes not enough to have a clinically relevant impact on observed effect size; 
 Missing data have been imputed using appropriate methods. 
Criteria for the judgement of 
‘NO’ (i.e. high risk of bias). 
Any one of the following: 
 Reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or 
reasons for missing data across intervention groups; 
 For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk enough 
to induce clinically relevant bias in intervention effect estimate; 
 For continuous outcome data, plausible effect size (difference in means or standardized difference in means) 
among missing outcomes enough to induce clinically relevant bias in observed effect size; 
 ‘As-treated’ analysis done with substantial departure of the intervention received from that assigned at 
randomization; 
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 Potentially inappropriate application of simple imputation. 
Criteria for the judgement of 
‘UNCLEAR’ (uncertain risk of 
bias). 
Any one of the following: 
 Insufficient reporting of attrition/exclusions to permit judgement of ‘Yes’ or ‘No’ (e.g. number randomized not 
stated, no reasons for missing data provided); 
 The study did not address this outcome. 
SELECTIVE OUTCOME REPORTING 
Are reports of the study free of suggestion of selective outcome reporting? [Short form: Free of selective reporting?] 
Criteria for a judgement of 
‘YES’ (i.e. low risk of bias). 
Any of the following: 
 The study protocol is available and all of the study’s pre-specified (primary and secondary) outcomes that are of 
interest in the review have been reported in the pre-specified way; 
 The study protocol is not available but it is clear that the published reports include all expected outcomes, 
including those that were pre-specified (convincing text of this nature may be uncommon). 
Criteria for the judgement of 
‘NO’ (i.e. high risk of bias). 
Any one of the following: 
 Not all of the study’s pre-specified primary outcomes have been reported; 
 One or more primary outcomes is reported using measurements, analysis methods or subsets of the data (e.g. 
subscales) that were not pre-specified; 
 One or more reported primary outcomes were not pre-specified (unless clear justification for their reporting is 
provided, such as an unexpected adverse effect); 
 One or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a 
meta-analysis; 
 The study report fails to include results for a key outcome that would be expected to have been reported for such 
a study. 
Criteria for the judgement of 
‘UNCLEAR’ (uncertain risk of 
bias). 
Insufficient information to permit judgement of ‘Yes’ or ‘No’. It is likely that the majority of studies will fall into 
this category. 
OTHER POTENTIAL THREATS TO VALIDITY 
Was the study apparently free of other problems that could put it at a risk of bias? [Short form: Free of other bias?] 
Criteria for a judgement of 
‘YES’ (i.e. low risk of bias). 
The study appears to be free of other sources of bias. 
Criteria for the judgement of There is at least one important risk of bias. For example, the study: 
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‘NO’ (i.e. high risk of bias).  Had a potential source of bias related to the specific study design used; or 
 Stopped early due to some data-dependent process (including a formal-stopping rule); or 
 Had extreme baseline imbalance; or 
 Has been claimed to have been fraudulent; or 
 Had some other problem. 
Criteria for the judgement of 
‘UNCLEAR’ (uncertain risk of 
bias). 
There may be a risk of bias, but there is either: 
 Insufficient information to assess whether an important risk of bias exists; or 
 Insufficient rationale or evidence that an identified problem will introduce bias. 
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Appendix G. Characteristics of included studies 
Study Design Disease studied Setting/Data source 
Accrual 
period 
Sample 
size 
Inclusion criteria 
(Exclusion criteria) 
Ajeganova et al., 2013
63
 Prospective 
cohort 
RA 
Better Anti-Rheumatic 
Pharmaco Therapy  
(BARFOT) (Sweden) 
1993-1999 741 
RA patients according to ACR criteria, age ≥18 
years, disease duration ≤12 months 
(Patients with prevalent CVD at the time of RA 
diagnosis) 
Bernatsky et al., 2005
64
 Nested 
Case-control 
RA 
Protocare longitudinal health 
benefit claims database and 
PharMetrics Integrated 
Outcomes Database 
(North America) 
1998-2001 5720 
RA patients, age ≥18 years, without history of 
CHF at the time of database entry, to have >3 
months of eligibility in the health insurance 
plan prior to main cohort entry 
Cases: RA with CHF (ICD-9, code 428), 
Controls: RA without CHF 
Bozaite-Gluosniene et 
al.,2011
65
 
Retrospective 
cohort 
RA 
Medical Centers, Danville, 
PA, USA 
2001-2008 1829 RA patients without pre-existing CAD 
Chiang et al., 2013
66
 Retrospective 
cohort 
Systemic 
sclerosis 
(SSc) 
Longitudinal Health Insurance 
Database2005, Taiwan 
1997-2006 1238 
SSc patients (ICD-9-CM, code 710.1), age ≥18 
years at the time of SSc diagnosis, without prior 
history of cerebrovascular disease 
Chin et al., 2013
67
 Retrospective 
cohort 
Psoriasis, 
psoriatic arthritis 
(PsA) 
Longitudinal Health Insurance 
Database 2005, Taiwan 
1997-2006 7932 
Newly diagnosed psoriasis patients (ICD-9, 
code without arthritis: 696.1, 696.8, with 
arthritis: 696.0), born between 1930 and 1990 
(Patients with severe vascular disease prior to 
psoriasis diagnosis, patients received both MTX 
and retinoid) 
Choi et al., 2002
113
 Prospective 
cohort 
RA 
Wichita Arthritis Center,  
USA 
1981-1999 1240 
RA patients fulfilling the 1958-1987 ACR 
criteria, age ≥18 years, without use of MTX 
before their first visit to the Center 
(Patients with contraindications for MTX use) 
Cohen et al., 2001
114
 
RCT RA 
Multicenter,  
North America 
Not 
specified 
318 
RA patients diagnosed by ACR criteria for ≥6 
months, age 18-75 years, not previously 
received MTX, and could not have been 
receiving other DMARDs for ≥30 days prior to 
trial entry 
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Study Design Disease studied Setting/Data source Accrual 
period 
Sample 
size 
Inclusion criteria 
(Exclusion criteria) 
Davis et al., 2013
75
 Prospective 
cohort 
RA 
Veterans Affairs RA 
(VARA) registry, 
Veterans Affairs 
medical centers, USA 
2003- 
unclear end 
date 
1047 
RA patients meeting 1987 ACR criteria and 
available for genotyping data for MTHER 
C677T and/or A1298C polymorphisms 
Edwards et al., 2008
68
 Retrospective 
cohort 
RA 
The UK General Practice 
Research Database (GPRD) 
1987-2002 34364 Adult patients with RA 
Gonzalez-Gay et al., 
2007
116
 
Prospective 
cohort 
RA 
Rheumatology 
outpatient clinic of  
Hospital Xeral-Calde,  
Lugo, Spain 
Mar 1996- 
Sept 1996 
182 
RA patients diagnosed as per ACR 1987 
criteria, consecutive unselected patients 
attending OPD between Mar-Sep 1996 
Goodson et al., 2008
111
 Prospective 
cohort 
Inflammatory 
polyarthritis 
The UK Norfolk Arthritis 
Register (NOAR), UK 
1990-1994 923 Patients with Inflammatory Polyarthritis (IP) 
Lan et al., 2012
69
 Retrospective 
cohort 
Psoriasis 
Longitudinal Health Insurance 
Database 2005, Taiwan 
1997-2006 8180 
Psoriasis patients(ICD-9 696.0, 696.1, 696.8), 
born between 1930 and 1990 
(patients with CVD before their first psoriasis 
diagnosis) 
Levesque et al., 2013
131
 Retrospective 
cohort 
Psoriasis 
RAMQ database, The public 
health plan, Province of 
Quebec, Canada 
2005-2010 5157 
Newly diagnosed psoriasis patients between 
2005-2010, age ≥20 years and used 
phototherapy, oral or injectable psoriasis 
treatment 
Mantel et al., 2014
110
 Nested case-
control 
RA 
Epidemiological Investigation 
of Rheumatoid Arthritis 
(EIRA) study, Sweden 
Not 
specified 
533 
Cases: RA patients experienced ACS following 
RA diagnosis. 
Controls: RA patients without ACS and 
matched with cases for sex, year of diagnosis 
and EIRA center 
Meek et al., 2014
70
 Prospective 
cohort 
RA 
The Arthritis Center Twente 
Cardiovascular Disease(ACT-
CVD) project, The 
Netherlands 
2009-2011 480 
RA patients, diagnosed by attending 
rheumatologist, without prior CVD and 
completed the CV screening protocol 
Mikuls et al., 2011
132
 Prospective 
cohort 
RA 
Veterans Affairs  
Rheumatoid Arthritis  
(VARA) registry, USA 
2002-2009 1015 
RA patients meeting 1987 ACR criteria, RA 
onset > 18 years of age (Women and RA 
patients with limited follow-up data) 
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Study Design Disease studied Setting/Data source Accrual 
period 
Sample 
size 
Inclusion criteria 
(Exclusion criteria) 
Myasoedova et al., 
2011
71
 
Retrospective 
cohort 
RA 
Rochester Epidemiology 
Project (REP) medical 
records linkage system, 
Minnesota, USA 
1980-2008 795 
Incident RA patients meeting 1987 ACR 
criteria, age ≥18 years 
(patients with personal history of heart failure) 
Nadareishvili et al., 
2008
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Nested 
case-control 
RA 
National Database for 
Rheumatic Diseases (NDB), 
USA 
Not 
specified 
832 
RA diagnosed by rheumatologist 
Cases: RA with Ischemic stroke 
Controls: RA without stroke 
(Cases with Intracerebral, subarachnoid, 
subdural, epidural hemorrhages, TIA) 
Norton et al., 2014
107
 Retrospective 
cohort 
RA 
32 rheumatology centres in the 
UK 
1986-2012 2763 DMARD naïve RA patients 
Pope et al., 2001
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RCT 
Systemic 
sclerosis 
(SSc) 
Multicenter, North America 
Not 
specified 
71 
SSc patients, age ≥18 years, diagnosed SSc 
within the past three years of study entry 
(Overlap syndrome, mixed CTD, morphea, 
linear scleroderma, contraindications to MTX 
treatment, current or past use of MTX) 
Prodanowich et al., 
2005
108
 
Retrospective 
cohort 
RA, psoriasis 
Veterans Health 
Administration Data Source, 
Miami, Florida, USA 
1998-2003 
Psoriasis
: 7615 
RA: 
6707 
(total: 
14322) 
Patients with psoriasis (ICD-9, code 696.1) or 
RA (ICD-9 code 714.0) or both diagnosis 
(Vascular diagnosis before the diagnosis of RA 
or psoriasis, MTX prescription after the 
diagnosis of vascular disease) 
Suissa et al., 2006
133
 Nested 
case-control 
RA 
PharMetrics Patient-Centric 
Outcomes Database, Insurance 
claims database, 
North America 
1999-2003 6138 
RA patients (ICD-9, code 714.0), age ≥18, no 
prior history of MI 
Cases: RA with AMI hospitalization (ICD-9, 
code 410) 
Controls: RA without AMI 
Tisseverasinghe et al., 
2009
118
 
Nested 
case-control 
Dermatomyositi
s,polymyositis 
Quebec provincial physician 
billing, hospitalization, and 
pharmacy database, Canada 
1994-2003 411 
Patients with DM or PM (ICD-9: 710.3-710.4) 
Cases: DM/PM with thrombotic event, 
Controls: DM/PM without thrombotic event 
(Patients with thrombotic events prior to the 
diagnosis of DM or PM) 
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Study Design Disease studied Setting/Data source Accrual 
period 
Sample 
size 
Inclusion criteria 
(Exclusion criteria) 
Troelsen et al., 2007
120
 Prospective 
cohort 
RA Clinical sites in Denmark 1995-1998 229 RA patients meeting ACR 1987 criteria 
van den Hoogen et al., 
1996
106
 RCT 
Systemic 
sclerosis 
(SSc) 
Multicenter trial,  
The Netherlands 
Not 
specified 
29 
SSc patients meeting American Rheumatism 
Association criteria, disease duration <3 years 
(age<16 years, presence of other CTD, 
contraindications to MTX use) 
van Halm et al., 2006
117
 
Case-control RA 
Jan van Breemen Institute, an 
outpatient clinic in 
Amsterdam,  
The Netherlands 
Not 
specified 
613 
RA patients fulfilling ACR criteria, without 
prior CV event 
Cases: RA with first CV event 
Controls: RA without CV event 
Wasko et al., 2013
119
 Prospective 
cohort 
RA 
10 rheumatology practices, 
North America 
1981-2005 5626 
RA patients fulfilling ACR 1987 criteria, age 
≥18 years 
Wolfe and Michaud, 
2008
112
 
Nested 
case-control 
RA 
National Databank for 
Rheumatic Diseases (NDB) 
longitudinal Study, USA 
Not 
specified 
9153 
RA diagnosed by rheumatologist 
Cases: RA with incident myocardial infarction 
(MI) 
Controls: RA without MI 
Wolfe et al., 2003
134
 Retrospective 
cohort 
RA 
Wichita Arthritis Center, an 
outpatient rheumatology 
clinic, USA 
1981-1999 1387 
RA patients fulfilling 1958 or 1987 ACR 
criteria 
(patients not seen for 2 years of their death) 
Wu et al., 2012
109
 Retrospective 
cohort 
Psoriasis, 
psoriatic arthritis 
Kaiser Permanente Southern 
California (KPSC) health plan, 
USA 
2004-2010 8845 
Psoriasis (ICD-9-CM code 696.1) or psoriatic 
arthritis (ICD-9-CM code 696.0) 
(prior history of MI (ICD-9-CM code 410.XX 
or 412)) 
Abbreviations: ACR: American College of Rheumatology, CHF: Congestive heart failure, CAD: Coronary artery disease, ICD: International Classification of 
Disease, MTX: Methotrexate, RCT: Randomized Controlled Trial, ACS: Acute coronary syndrome, TIA: Transient ischemic attack, DMARD: Disease 
Modifying Anti-Rheumatic Drugs, CTD: Connective tissue disease, AMI: Acute myocardial infarction, DM: Dermatomyositis, PM: Polymyositis 
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Appendix H. Characteristics of disease in each study 
Study Disease under study Diagnostic criteria Disease duration 
Ajeganova et al., 2013 RA ACR criteria ≤ 12 months 
Bernatsky et al., 2005 RA Patients with ICD-9, code 714 Not specified 
Bozaite-Gluosniene et al.,2011 RA Diagnosed by treating physician Not specified 
Chiang et al., 2013 Systemic sclerosis Patients with ICD-9-CM code 710.1 Not specified 
Chin et al., 2013 
Psoriasis, 
psoriatic arthritis 
Patients with ICD-9 code 696.1,  
696.8, and 696.0 
Newly diagnosed 
Patients 
Choi et al., 2002 RA 1958-1987 ACR criteria 
Mean (SD): 
9.0 (9.4) years 
Cohen et al., 2001 RA ACR criteria Mean 6.5 years 
Davis et al., 2013 RA 1987 ACR criteria 
Mean (SD): 
14.5 (12.2) years 
Edwards et al., 2008 RA Criteria not specified Not specified 
Gonzalez-Gay et al., 2007 RA 1987 ACR criteria 
Mean, Median (IQR): 
10.5, 8, (4-14) years 
Goodson et al., 2008 
Inflammatory 
polyarthritis 
Patients with polymyositis  
and Dermatomyositis 
Not specified 
Lan et al., 2012 Psoriasis 
Patients with ICD-9 code  
696.0, 696.1, 696.8 
Not specified 
Levesque et al., 2013 Psoriasis 
Newly diagnosed patients,  
Criteria not specified 
Not specified 
Mantel et al., 2014 RA Not specified Not specified 
Meek et al., 2014 RA 
Diagnosed by attending  
Rheumatologist 
Median (IQR): 
4.2 (1.5-11.3) years 
Mikuls et al., 2011 RA 1987 ACR criteria 
Mean (SD): 
12 (12) years 
Myasoedova et al., 2011 RA 1987 ACR criteria Not specified 
Nadareishvili et al., 2008 RA 
Diagnosed by treating  
Rheumatologist 
Mean (SD): 
15.9 (13.5) years 
Norton et al., 2014 RA Not specified Not specified 
Pope et al., 2001 Systemic sclerosis 
ACR preliminary criteria  
for Scleroderma 
Mean (SEM) months: 6.3 (1.0) (MTX), 7.3 
(1.1) (placebo) 
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Study Disease under study Diagnostic criteria Disease duration 
Prodanowich et al., 2005 RA, psoriasis 
Patients with ICD-9 code 696.1 for psoriasis or 
ICD-9 code 714.0 for RA 
Not specified 
Suissa et al., 2006 RA Patients with ICD-9 code 714.0 Not specified 
Tisseverasinghe et al., 2009 
Dermatomyositis, 
Polymyositis 
Patients with ICD-9 codes  
710.3-710.4 
Not specified 
Troelsen et al., 2007 RA 1987 ACR criteria Median (range): 6.3 (0.1-54) years 
van den Hoogen et al., 1996 Systemic sclerosis 
American Rheumatism  
Association criteria 
Mean (SD): 
3.2 (6.3) years 
van Halm et al., 2006 RA ACR criteria 
Median 
Cases: 7.7 years 
Controls: 10.6 y. 
Wasko et al., 2013 RA 1987 ACR criteria 
Mean (SD): 
10.58 (10.26) years 
Wolfe and Michaud, 2008 RA Diagnosed by treating rheumatologist Median: 12.2 years 
Wolfe et al., 2003 RA 1958 or 1987 ACR criteria Mean (SD): 7.06 (8.52) years 
Wu et al., 2012 
Psoriasis, 
psoriatic arthritis 
ICD-9-CM code 696.1, 696.0 Not specified 
Abbreviations: RA: Rheumatoid arthritis, ACR: American College of Rheumatology, ICD: International Classification of Diseases 
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Appendix I. Exposure characteristics 
Study Data source of MTX exposure MTX Exposure Exposure definition 
Ajeganova et al., 2013 
Better Anti-Rheumatic 
Pharmaco Therapy  registry 
Ever-users vs. never-users 
(67.2% MTX users) 
Regular use: >6 months during observation period 
Bernatsky et al., 2005 Insurance claim database 
Current-users vs. non-users 
MTX users: cases (29%), controls 
(36%)  
A prescription dispensed during the 45 days period 
prior to the outcome (CHF) 
Bozaite-Gluosniene et al.,2011 Medical records 
Ever-users vs. never-users 
Ever users: 61% 
Never users: 39% 
Time-varying use of MTX, medication start and stop 
date before CAD diagnosis or censor date 
Chiang et al., 2013 
Longitudinal Health Insurance 
Database (LHID2000), Taiwan 
Ever-users vs. never-users 
> 6 months of therapy before reaching primary 
endpoint, death, or end of follow-up 
Chin et al., 2013 
Longitudinal Health Insurance 
Database (LHID2000), Taiwan 
Ever-users vs. never-users Prescription drug claims of MTX 
Choi et al., 2002 
Wichita Arthritis Center medical 
records, USA 
Initiators vs. non-initiators 
(mean dose 13 mg per week 
maximum dose 25 mg per week) 
Once a patient starts MTX therapy, he or she was 
considered on therapy for the rest of the follow-up 
(intension-to-treat approach) 
Cohen et al., 2001 Medical records 
Initiators vs. placebo 
Dose: 15 to 17.5 or 20 mg/week.  
MTX naïve patients were randomized to MTX or 
placebo 
Davis et al., 2013 VARA clinical database, USA 
Initiators vs. non-initiators 
MTX initiators: 51.2% 
MTX exposure at the time of study enrollment (yes/no) 
Edwards et al., 2008 
General Practice Research Database, 
UK 
Ever-users vs. never-users 
Prescription of DMARDs compared to no prescription 
during study period 
Gonzalez-Gay et al., 2007 
Medical records, 
Rheumatology clinic, Spain  
Ever-users vs. never-users 
Medication prescribed at study start and changes noted 
during follow-up period 
Goodson et al., 2008 
Medical records, 
UK Norfolk Arthritis Register 
Current-users vs. never-users 
MTX users: 23% 
Current medication was recorded annually for 6 years 
& then every 2-3 years,  
Time-varying use of MTX in analysis 
Lan et al., 2012 
Longitudinal Health Insurance 
Database 2005, Taiwan 
Ever-users vs. never-users 
Prescription claims of MTX were identified from the 
database 
Levesque et al., 2013 
RAMQ Health plan database, 
Canada 
Ever-users vs. never-users 
MTX users: 23.7% 
Treatment identified from the database 
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Study Data source of MTX exposure MTX Exposure Exposure definition 
Mantel et al., 2014 
Medical charts, patient register, 
National Prescribed Drug Register 
Unclear MTX use in cases and controls was identified 
Meek et al., 2014 
Medical records, The Arthritis 
Center Twente, The Netherlands 
Initiators vs. non-initiators 
MTX: 60.6% 
Baseline MTX users at study start 
Mikuls et al., 2011 
Medical records, VARA registry 
USA 
Current-users vs. never-users 
MTX use at baseline and follow-up visits, analyzed as a 
time-varying use  
Myasoedova et al., 2011 
Medical records, REP medical 
record linkage system, USA 
Current users vs. never-users 
Time-dependent variable represented the time each 
patient was taking medication  
Nadareishvili et al., 2008 Patient self-report in questionnaire Initiators vs. non-initiators Baseline use of MTX reported by patients 
Norton et al., 2014 Medical records Initiators vs.  non-initiators Time-varying use of MTX in DMARD naïve  patients 
Pope et al., 2001 Medical records Initiators vs. Placebo Patients were randomized to MTX or placebo treatment 
Prodanowich et al., 2005 Computerized medical records Ever-users vs. never-users 
MTX prescriptions vs. no-MTX prescriptions before the 
development of vascular disease 
Suissa et al., 2006 Dispensed prescription data 
Current users vs. non-current 
users 
Prescription dispensed during the 30-day period prior to 
the AMI in cases 
Tisseverasinghe et al., 2009 
Pharmacy database and physician 
billing data 
Ever-users vs. never-users 
MTX: 26.3% 
≥ 1 prescription for the given drug, any time between 
cohort entry and index date 
Troelsen et al., 2007 Medical charts 
Current users vs. non-current 
users, MTX: 81% patients 
Use of MTX reported in clinical charts 
van den Hoogen et al., 1996 Medical records Initiators vs. placebo Patients were randomized to MTX and placebo 
van Halm et al., 2006 Medical records 
Ever-users vs. never-users,  
MTX (Cases): 72% 
MTX (controls): 44% 
Medication use was identified either as monotherapy or 
in combinations 
Wasko et al., 2013 
Patient self-report in semi-annual 
questionnaire 
Current-users vs. non-users 
MTX use was assessed as time-varying variable in the 
analysis 
Wolfe and Michaud, 2008 Patient self-report in questionnaire 
Current-users vs. never-users, 
Average MTX dose: 14mg/week 
Patients receiving MTX within 6 months prior to their 
first MI  
Wolfe et al., 2003 Medical records Ever-users vs. never-users 
MTX use was assessed as time-varying variable in the 
analysis 
Wu et al., 2012 KPSC pharmacy database Ever-users vs. never-users 
The date of the first dispensation of any non–TNF 
inhibitor systemic agent after the third psoriasis 
diagnosis 
Abbreviations: CHF: Congestive heart failure, VARA: Veterans Affairs Rheumatoid Arthritis, REP: Rochester Epidemiology Project, AMI: acute myocardial 
infarction, KPSC: Kaiser Permanente Southern California  
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Appendix J. Outcome characteristics 
Study Data source of outcomes Outcome Definition Excluded patients 
with prior or 
current CVD 
Ajeganova et al., 2013 
Swedish Hospital Discharge 
Registry  
National Cause of Death 
Registry, Sweden 
CVD 
All-cause mortality 
First ever CVD (ICD-9 and ICD-10 codes for 
CVD: 410, 411, 413, 427F, 433-436, 440-444, 
3066-3067, 3080, 3092, 3105, 3127, 3141, 3158, 
88, 0961-0964, I20-21, Y832, I46, I63-I66, G45, 
I70-I72, I73.9, and I74), 
Mortality regardless of cause 
Yes 
Bernatsky et al., 2005 Hospitalization records 
CHF requiring 
hospitalization 
First ever hospitalization due to  
CHF (ICD-9 code 428) 
No 
Bozaite-Gluosniene et 
al.,2011 
Medical center records 
Coronary artery disease 
Cardiac revascularization 
procedure 
First ever CAD  
(ICD-9 code 410-419.99) 
Yes 
Chiang et al., 2013 
Insurance claim database, 
Hospital records, outpatient visit 
records, prescriptions claims for 
stroke medications 
Ischemic stroke ICD-9-CM codes 433 - 435 No 
Chin et al., 2013 Physician claims 
Cerebrovascular events 
Cardiovascular events 
Cardiovascular events: ICD9 codes 410 - 414.05, 
414.10, 414.11, 414.19, 414.8 - 414.9, 429.79 
Cerebrovascular events: ICD9 codes 430.0 - 438.9 
Yes 
Choi et al., 2002 
Medical records, Death 
certificates, National Death 
Index, USA 
All-cause mortality 
Cardiovascular mortality 
Cause of death according to ICD-9 codes, for 
Cardiovascular mortality: ICD-9 codes 390 - 449 
No 
Cohen et al., 2001 Medical records All-cause mortality Death as an adverse event Not specified 
Davis et al., 2013 
Inpatients and outpatients  
treatment files 
Cardiovascular events 
All-cause mortality 
First occurrence of any of the CV events: MI 
(ICD-9 code 410.x), Stroke (ICD-9 codes 433.11, 
434.91, 435.x, 438.x), PCI (ICD-9 codes 36.06, 
36.07, 0.66; CPT: 92973, 92980, 92995), CABG 
(ICD-9 codes 36.1x) 
No 
Edwards et al., 2008 Outpatient records, GPRD, UK Myocardial infarction Incidence of MI Not specified 
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Study Data source of outcomes Outcome Definition Excluded patients 
with prior or 
current CVD 
Gonzalez-Gay et al., 
2007 
Medical records 
Cardiovascular events 
Cardiovascular mortality 
Any CV event diagnosed at the hospital in a 
patient without previous history of CVD. IHD 
included ACS with or without persistent ST-
segment elevation and chronic CHD. 
Cerebrovascular accident included stroke/TIAs 
Yes 
Goodson et al., 2008 Medical records 
All-cause mortality 
Cardiovascular mortality 
Mortality regardless of cause and cardiovascular 
mortality 
Not specified 
Lan et al., 2012 
Inpatients and outpatients 
physician claims in Longitudinal 
Health Insurance Database 2005, 
Taiwan 
Cerebrovascular event 
First occurrence of cerebrovascular event (ICD-9 
codes 430.0–438.9) 
Yes 
Levesque et al., 2013 
Health plan database, Quebec, 
Canada 
Myocardial infarction 
Acute MI diagnosis consistent with an ICD-9 code 
for MI 
No 
Mantel et al., 2014 
National Patient Register and 
Cause of Death Register, 
Sweden 
Acute coronary syndrome 
Hospitalization or cause-of-death listing ACS 
following RA diagnosis 
No 
Meek et al., 2014 
Hospital Electronic Registration 
System, Medical chart review, 
Dutch National Registry of 
Death Certificates, The 
Netherlands 
Cardiovascular event 
 
CV events (fatal/non-fatal) included MI, PTCA, 
CABG, angina pectoris, acute heart failure, CVA, 
death due to cardiac causes and sudden death, 
diagnosis was confirmed by a cardiologist 
Yes 
Mikuls et al., 2011 
Veterans Affairs Computerized 
Patient Record System (CPRS), 
USA 
All-cause mortality 
Identified through systematic review of the 
Veterans Affairs CPRS 
No 
Myasoedova et al., 2011 
Rochester Epidemiology Project 
(REP) medical records linkage 
system, USA 
Heart failure 
Based on the Framingham criteria* for diagnosis 
of heart failure 
No 
Nadareishvili et al., 2008 
Hospitalization records, 
physician reports and death 
records, confirmed by medical 
review or death records. 
Ischemic stroke 
Included ICD-9 codes 433.01 - 433.80 and 434 - 
434.91. Excluded intracerebral, subarachnoid, 
subdural, and epidural hemorrhages and TIA 
No 
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Study Data source of outcomes Outcome Definition Excluded patients 
with prior or 
current CVD 
Norton et al., 2014 
National Health Service (NHS)  
central register, UK 
All-cause mortality Confirmed by death certificates from NHS register  Not specified 
Pope et al., 2001 Medical records All-cause mortality Death as an adverse event Not specified 
Prodanowich et al., 2005 
Computerized outpatient 
medical records 
CVD 
CVD (ICD-9-CM codes 410.0-410.02, 410.1-
411.0, 411.89, 413.0-413.9, 414.0-414.9, 429.2), 
Cerebrovascular disease (ICD-9-CM codes 433.0-
433.9, 434-436), Atherosclerosis ( ICD-9-CM 
codes 440.0-440.9) 
Yes 
Suissa et al., 2006 
Hospitalization physician  
records 
Myocardial infarction 
First occurrence of AMI requiring hospitalization 
(ICD-9 code 410) 
No 
Tisseverasinghe et al., 
2009 
Hospital records and physician  
billing data 
CVD 
≥1 hospital diagnosis or ≥2 relevant billing codes, 
≥8 weeks apart for stroke (ICD-9 code 433.5.x), 
IHD (410-1.x, 413.x), PAD (444-5.x) or AMI (≥1 
hospitalization) 
No 
Troelsen et al., 2007 
Discharge diagnosis from 
hospitalization records 
IHD 
MI 
Verified diagnosis by reviewing clinical charts, 
IHD (ICD-10 code I20-I25), MI (ICD-10: I21-I22) 
Not specified 
Van den Hoogen et al., 
1996 
Medical records All-cause mortality Death as an adverse event No 
Van Halm et al., 2006 
Medical records from 
rheumatology outpatient clinic, 
Amsterdam 
CVD 
First CV event. A verified medical history of 
coronary (MI, CABG, PTCA, ischemic 
abnormality on ECG), cerebral (CVA (confirmed 
by neurologist), TIA, Carotid endarterectomy) or 
peripheral arterial disease 
Yes 
Wasko et al., 2013 
National Death Index ,  
North America 
All-cause mortality 
Death was ascertained by communication with 
next of kin or by searching the National Death 
Index 
No 
Wolfe and Michaud, 
2008 
Study questionnaire, hospital  
records, physician reports, and 
death records 
Myocardial infarction 
MI confirmed by medical or death records review 
by independent physician 
No 
Wolfe et al., 2003 
Medical records, death 
certificates and the National 
Death Index, USA 
All-cause mortality 
Deaths were confirmed by review of medical 
records and death certificates, specific causes of 
death were classified using ICD-9 codes 
Not specified 
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Study Data source of outcomes Outcome Definition Excluded patients 
with prior or 
current CVD 
Wu et al., 2012 
Kaiser Permanente Southern 
California EMR, USA 
Myocardial infarction 
First occurrence of fatal or non-fatal MI (ICD-9-
CM code 410.XX or 412) 
Yes 
 
Abbreviations: GPRD: General Practitioner Research Database, CVD: Cardiovascular disease, CHF: Congestive heart failure, CV: Cardiovascular, IHD: 
Ischemic heart disease, CHD: Coronary heart disease, ACS: Acute coronary syndrome, TIA: Transient ischemic attack, PTCA: Percutaneous transluminal 
coronary angioplasty, CABG: Coronary artery bypass graft, AMI: Acute myocardial infarction, ECG: Electrocardiogram 
*Framingham criteria: HF diagnosis requires ≥ 2 of the major criteria [i.e., paroxysmal nocturnal dyspnea or orthopnea, neck vein distention, rales, radiographic cardiomegaly (i.e., 
increasing heart size on chest radiograph), acute pulmonary edema, S3 gallop, increased central venous pressure ≥ 16 cm of water at the right atrium, circulation time ≥ 25 seconds, 
hepatojugular reflux, weight loss > 4.5 kg in 5 days in response to treatment of congestive HF)], or the presence of 1 major criterion and ≥ 2 minor criteria (i.e., bilateral ankle 
edema, nocturnal cough, dyspnea on ordinary exertion, hepatomegaly, pleural effusion, decrease in vital capacity by 33% from maximal value recorded, and tachycardia rate ≥ 120 
beats/min). Minor criteria were counted only if they could not be attributed to another medical condition. Ejection fraction (EF) was determined by echocardiography and classified 
as preserved EF (≥ 50%) or reduced EF (< 50%) 
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Appendix K. Data for subgroup analysis and meta-regression for primary outcome (cardiovascular events) 
Study Publication 
year 
Disease Study design Study 
region 
Sample 
size 
Mean 
age 
(years) 
% Female Observation 
period (person-
years) 
MTX 
exposure type 
Ajeganova  2013 RA Prospective Europe 741 55 67.5 9405 Ever-users 
Davis  2013 RA Prospective America 1047 63.7 9.07 3743 Initiators 
Gonzalez-Gay  2007 RA Prospective Europe 182 59.7 72 NA Ever-users 
Meek et al 2014 RA Prospective Europe 480 59 72.3 1380 Initiators 
Prodanowich  2005 Psoriasis Retrospective America 7615 NA 5.39 NA Ever-users 
Prodanowich  2005 RA Retrospective America 6707 NA 10.15 NA Ever-users 
Tisseverasinghe 2009 DM,PM Case-control America 411 62.4 70 0 Ever-users 
Van Halm 2006 RA Case-control Europe 613 64.72 70.35 0 Ever-users 
 
 
Study Exposure 
source 
Excluded 
patients 
with 
CVD 
MTX as 
time-
varying 
in 
analysis 
Adjusted 
DMARDs 
in 
analysis 
Number 
of  CV 
events 
Adjusted 
for CV 
risk 
factors 
Adjusted 
for 
smoking 
Adjusted 
for CVD 
Quality 
score 
Power 
score 
Ajeganova  Database yes no no 177 yes yes no 9 0.99 
Davis  Database no no no 97 no no no 6 0.88 
Gonzalez-Gay  Medical records yes no no 39 no no no 8 0.60 
Meek et al Medical records yes no yes 29 yes yes no 8 0.11 
Prodanowich  Medical records yes no no 1869 yes no no 9 1.00 
Prodanowich  Medical records yes no no 2017 yes no no 9 1.00 
Tisseverasinghe Database no no yes 80 yes no yes 7 0.41 
Van Halm Medical records yes no no 72 yes yes no 7 0.08 
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Appendix L. Methodological quality of cohort studies according to the Newcastle Ottawa Scale 
Study Representativeness 
of exposed cohort 
(1 point) 
Selection 
of non-
exposed 
cohort 
(1 point) 
Ascertainment 
of exposure 
(1 point) 
Demonstration 
that outcome of 
interest was not 
present at baseline 
(1 point) 
Comparability 
of cohorts on the 
basis of the 
design or 
analysis 
(2 points) 
Assessment 
of outcome 
(1 point) 
Follow-
up long 
enough 
for 
outcomes 
to occur 
(1 point) 
Adequacy 
of follow 
up of 
cohorts 
(1 point) 
Total 
score 
(9 pts) 
 
Ajeganova 1 1 1 1 2 1 1 1 9 
          
Bozaite-Gluosniene 1 1 1 1 2 1 1 1 9 
          
Chiang  1 1 1 1 1 1 1 1 8 
          
Chin  1 1 1 1 1 1 1 1 8 
          
Choi  1 1 1 0 2 1 1 1 8 
          
Davis 1 1 1 0 1 1 0 1 6 
          
Edwards 1 1 1 0 1 1 1 1 7 
          
Gonzalez-Gay  1 1 1 1 1 1 1 1 8 
          
Goodson 1 1 1 0 2 0 1 1 7 
          
Lan 1 1 1 1 1 1 1 1 8 
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Levesque 1 1 1 0 2 1 1 1 8 
          
Meek 1 1 1 1 2 1 0 1 8 
          
Mikuls  1 1 1 1 2 1 1 1 9 
          
Myasoedova  1 1 1 1 2 1 1 1 9 
          
Norton 1 1 1 1 2 1 1 1 9 
          
Prodanowich  1 1 1 1 2 1 1 1 9 
          
Troelsen  1 1 1 0 2 1 1 1 8 
          
Wasko 1 1 1 1 2 1 1 1 9 
          
Wolfe  1 1 1 1 2 1 1 1 9 
          
Wu  1 1 1 1 2 1 1 1 9 
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Appendix M. Methodological quality of case-control studies according to the Newcastle Ottawa Scale 
Study Adequate 
case definition 
(1 point) 
Representa-
tiveness of 
the cases 
(1 point) 
Selection of 
controls 
(1 point) 
Definition 
of controls 
(1 point) 
Comparability 
of cases and 
controls on the 
basis of the 
design or 
analysis 
(2 points) 
Ascertainment 
of exposure 
(1 point) 
Same method 
Of 
ascertainment 
for cases and 
controls 
(1 point) 
Non-Response 
rate 
(1 point) 
Total 
score 
(9 pts) 
Bernatsky 0 1 1 1 2 0 1 1 7 
          
Mantel  0 1 1 1 1 0 1 1 6 
          
Nadareishvili  1 1 1 1 2 0 1 1 8 
          
Suissa 0 1 1 1 2 0 1 1 7 
          
Tisseverasinghe  0 1 1 1 2 0 1 1 7 
          
van Halm  0 1 1 1 2 0 1 1 7 
          
Wolfe and 
Michaud. 
1 1 1 1 2 0 1 1 8 
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Appendix N. Risk of bias assessment of randomized controlled trials (n=3) 
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